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WHAT IS A WITNESS SEMINAR?
The Witness Seminar is a specialized form of oral history, where several 
individuals associated with a particular set of circumstances or events are invited 
to meet together to discuss, debate, and agree or disagree about their memories. 
The meeting is recorded, transcribed, and edited for publication. 
This format was first devised and used by the Wellcome Trust’s History of 
Twentieth Century Medicine Group in 1993 to address issues associated with 
the discovery of monoclonal antibodies. We developed this approach after 
holding a conventional seminar, given by a medical historian, on the discovery 
of interferon. Many members of the invited audience were scientists or others 
involved in that work, and the detailed and revealing discussion session 
afterwards alerted us to the importance of recording ‘communal’ eyewitness 
testimonies. We learned that the Institute for Contemporary British History 
held meetings to examine modern political, diplomatic, and economic history, 
which they called Witness Seminars, and this seemed a suitable title for us to 
use also. 
The unexpected success of our first Witness Seminar, as assessed by the 
willingness of the participants to attend, speak frankly, agree and disagree, and 
also by many requests for its transcript, encouraged us to develop the Witness 
Seminar model into a full programme, and since then more than 50 meetings 
have been held and published on a wide array of biomedical topics.1 These 
seminars have proved an ideal way to bring together clinicians, scientists, and 
others interested in contemporary medical history to share their memories. We 
are not seeking a consensus, but are providing the opportunity to hear an array 
of voices, many little known, of individuals who were ‘there at the time’ and 
thus able to question, ratify, or disagree with others’ accounts – a form of open 
peer-review. The material records of the meeting also create archival sources for 
present and future use.
The History of Twentieth Century Medicine Group became a part of the 
Wellcome Trust’s Centre for the History of Medicine at UCL in October 
2000 and remained so until September 2010. It has been part of the School 
of History, Queen Mary University of London, since October 2010, as the 
History of Modern Biomedicine Research Group, which the Wellcome Trust 
1  See pages 113–18 for a full list of Witness Seminars held, details of the published volumes and other 
related publications.
vi
funds principally under a Strategic Award entitled ‘The Makers of Modern 
Biomedicine’. The Witness Seminar format continues to be a major part of that 
programme, although now the subjects are largely focused on areas of strategic 
importance to the Wellcome Trust, including the neurosciences, clinical 
genetics, and medical technology.2
Once an appropriate topic has been agreed, usually after discussion with 
a specialist adviser, suitable participants are identified and invited. As the 
organization of the Seminar progresses and the participants’ list is compiled, a 
flexible outline plan for the meeting is devised, with assistance from the meeting’s 
designated chairman/moderator. Each participant is sent an attendance list and 
a copy of this programme before the meeting. Seminars last for about four 
hours; occasionally full-day meetings have been held. After each meeting the 
raw transcript is sent to every participant, each of whom is asked to check his or 
her own contribution and to provide brief biographical details for an appendix. 
The editors incorporate participants’ minor corrections and turn the transcript 
into readable text, with footnotes, appendices, a glossary, and a bibliography. 
Extensive research and liaison with the participants is conducted to produce 
the final script, which is then sent to every contributor for approval and to 
assign copyright to the Wellcome Trust. Copies of the original, and edited, 
transcripts and additional correspondence generated by the editorial process are 
all deposited with the records of each meeting in the Wellcome Library, London 
(archival reference GC/253) and are available for study.
For all our volumes, we hope that, even if the precise details of the more 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable to all readers. Our aim is that the volumes 
inform those with a general interest in the history of modern medicine and 
medical science; provide historians with new insights, fresh material for study, 
and further themes for research; and emphasize to the participants that their 
own working lives are of proper and necessary concern to historians.
2  See our group’s website at www.histmodbiomed.org 
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It is a great privilege for me to be invited to introduce this Witness Seminar on 
Brain Banking in the UK. My background in this field started in 1980 when, 
after graduating in medicine in the University of Dundee and completing my pre-
registration posts in medicine and surgery, I started my postgraduate specialization 
in histopathology. I have always been more interested in mechanisms of disease 
rather than treatment; this speciality allowed me to begin study of the tissue-
based changes occurring in disease both for diagnosis and research. 
After gaining the knowledge required to pass the first part of the examination for 
Membership of the Royal College of Pathologists (MRCPath), I was given some 
time to develop a research interest. I was fortunate at the time to be able to work 
with Dr John Anderson, who was interested in neuropathology in the elderly, in 
particular the changes occurring in the brain in Alzheimer’s disease and in normal 
ageing. He and his research assistant, Dr Beth Hubbard, used a collection of 
brains donated for research to work on precise volumetric methods to measure the 
severity of cerebral atrophy in Alzheimer’s disease and normal ageing, combined 
with detailed quantitative studies of the histological abnormalities of the brain. 
This work interested me greatly, and I decided to specialize in neuropathology.
In 1983 I obtained a training post in neuropathology in Sheffield with Dr 
(now Professor) Walter Timperley, who gave me an invaluable broad experience 
of all aspects of neuropathology, particularly in the detailed examination of 
brains for diagnosis and research. He had a well-established interest in forensic 
neuropathology and in vascular disorders of the brain, both based on the 
examination of a large series of brains. Although there was no formal Brain 
Bank in Sheffield at that time, there was a rich archive of material available for 
study. I was encouraged to use this to begin my career in research, which gave 
me an opportunity to establish an interest in neuro-oncology.
I was able to continue this interest in 1986 in my next position as Lecturer 
and then (having passed the final MRCPath examination in Neuropathology) 
Senior Lecturer in the University of Leeds, the same year that the first case 
of bovine spongiform encephalopathy (BSE) was identified in the UK.1 The 
subsequent epizootic of BSE and its emergence in domestic cats and other 
species focussed my attention on the rare spongiform encephalopathies in 
1  Wells et al. (1987).
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humans. I encountered cases of sporadic Creutzfeldt-Jakob disease (CJD) and 
the very rare Gerstmann-Straussler-Scheinker syndrome in Leeds, and I later 
became aware of a plan to establish a national surveillance project for CJD and 
related disorders in the UK, to establish whether any changes in this disease 
attributable to BSE might occur.
This project was to be led by Dr (now Professor) Robert Will, a Neurologist 
in Edinburgh, who had previously worked on a surveillance project of CJD in 
Oxford. Unexpectedly, a Consultant Neuropathologist post became available in 
Edinburgh in 1990, and I was delighted to be appointed to this post to work with 
Robert Will and my neuropathology colleague Dr (now Professor) Jeanne Bell. 
Jeanne had already established a Brain Bank in Edinburgh funded by the Medical 
Research Council (MRC) to study the effects of HIV/AIDS on the brain and 
other organs. I was very happy to support Jeanne in this work and she became 
an internationally recognised expert in this field. She felt that a similar approach 
would be essential for the CJD Surveillance project, but this would require 
the co-operation of Neuropathologists across the UK, not just in Edinburgh. 
Jeanne received funding from the Department of Health in 1991 to set up a 
Neuropathology Laboratory to support the CJD Surveillance project, including 
the establishment of a Brain Bank for CJD. In view of the national importance of 
this work we managed to obtain the support of colleagues in UK Neuropathology, 
but I have to say that inevitably some colleagues took more persuasion than others!
Over the next few years the CJD brain bank grew and was widely used, proving 
invaluable in 1996 when we reported the first cases of a new disease now known 
as variant CJD, which represents the result of BSE infection in humans.2 The 
recognition of this disorder is a tribute to the surveillance mechanisms for CJD 
in the UK, and to our colleagues in Neuropathology who supported our work. 
Without the CJD Brain Bank and the availability of CJD brains in Oxford 
from the earlier surveillance project in the 1980s, variant CJD could not have 
been identified at such an early stage. 
This work and the many other successes resulting from brain banking activities 
across the UK were thrown into jeopardy by the Alder Hey scandal in 1999 
and the findings of the Redfern Report in 2001 on the retention of organs at 
autopsy without the consent of relatives.3 This report led to the Human Tissue 
2  Will et al. (1996). 
3  See pages 24–31 passim and note 45. 
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Act 2004, which created a new body, the Human Tissue Authority (HTA), 
to regulate the retention, storage and use of human tissue in a wide range of 
settings, including post mortem examinations and research.4 
My conviction that human organs and tissues were essential for medical research, 
particularly for neurological disorders, led me to apply to be a Professional 
Member of the HTA. In April 2005, I joined my fellow pathologists Professor 
James Underwood (whom I knew well from my time in Sheffield) and Professor 
El-Nasir Lalani (whom I knew from my time in Leeds) as Members of the HTA 
Board under the Chairmanship of Baroness Helene Haywood. Over the next 
four years, my work with the HTA helped create the regulatory framework 
for the use of human tissues in medical research, after much engagement and 
debate with the research community. This regulatory framework is still evolving 
and hopefully will continue give both the public and researchers confidence to 
allow this essential work to proceed.
During the early years of the twenty-first century, the requirement for brain 
banking to support medical research in the UK was becoming more apparent 
and it was also becoming clear that the needs of key researchers, particularly for 
control brain samples, were not always being met. Professor Jeanne Bell tackled 
this particular problem with characteristic imagination and vigour, and secured 
MRC funding in 2005 for the Sudden Death Brain Bank in Edinburgh, aimed 
at collecting the control samples required by researchers.5 In 2006, the MRC 
held a Workshop to review brain banking activities and needs across the UK, 
after which a Steering Committee formulated recommendations to improve 
these activities in a Report in 2008 to the UK Clinical Research Collaboration 
‘Towards a National Framework for Brain Banking in the UK’.6 This report 
proposed that brain banking in the UK should be organised into a network, 
with a central co-ordination centre run by a Director.
After much consultation and discussions with colleagues, I applied for the Director’s 
post and was appointed in 2009, establishing the co-ordinating centre for the MRC 
UK Brain Bank Network in Edinburgh. Over the next four years, I worked first 
with Dr Catherine Moody and then Dr Joanna Jenkinson in the MRC to establish 
the Network, set up an operational and regulatory framework and formulate a 
4  The Human Tissue Authority, www.hta.gov.uk (visisted 19 January 2015).
5  See page 41 and Appendix 2.
6  UKCRC Brain Bank Strategy Advisory Committee (2008). See the discussion on pages 56–58. 
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plan of work that addressed the issues raised in the 2008 Report.7 It was a great 
pleasure to work with Catherine, Joanna and my neuropathology colleagues in the 
UK Brain Banks to make the Network a reality, during which I was greatly assisted 
by Mr Chris Tindall as the Database Manager and Mrs Sheila Clarke as my PA for 
the Network. By the end of my appointment in 2013, the Network was a well-
established functional entity, the need for brain banking in the twenty-first century 
had been well recognised,8 the MRC had renewed the funding of the four UK MRC 
Brain Banks for another five years, and an online database of over 9,000 brain tissue 
samples available across the UK was opened to researchers, who have made good use 
of this new resource.9 One of my final tasks as Director was to co-chair the MRC 
Brain Donation Workshop,10 which identified future priorities for the Network. 
Professor Seth Love will very capably take forward the actions from this Workshop 
as the new Director of the MRC UK Brain Bank Network.
As I have described above, much of my career in neuropathology has been 
spent in various matters directly concerning brain banking, so I was very 
disappointed not to be able to attend this Witness Seminar. The transcript has 
made fascinating reading and I am sure will be both interesting and informative 
to a much wider readership.
Professor James W Ironside










7  UKCRC Brain Bank Strategy Advisory Committee (2008).
8  Samarasekera et al. (2013). 
9  See page 57. 
10  MRC Brain Donation Workshop, www.mrc.ac.uk/documents/pdf/mrc-brain-donation-workshop/ 
(visited 19 January 2015).
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Professor Tilli Tansey: Good afternoon ladies and gentlemen. May I begin by 
welcoming you to the Wellcome Trust and thanking you all very much for 
coming to this Witness Seminar on the history of brain banks. The purpose of 
these meetings is to try to get behind the published stories to learn what really 
happened, not just the formal scientific literature or Research Council funding 
report. But who were the drivers? Who were the people who really moved things 
ahead? Why and when? Did some ideas not come to fruition? So we want you to 
tell us what happened in your own careers. We want to hear the authentic voices 
of brain banking in the UK in the past 40 or so years, and perhaps even to go 
a little behind that to what happened before the brain banks started (Table 1). 
This Witness Seminar came about as a result of the British Neuroscience 
Association meeting in April this year that was held at the Barbican.1 I’m sure 
several of you were there. I met Paul Francis there and talked with him about 
his work. I’d been interested in brain banks as a casual academic interest since 
leaving the lab myself, having worked on MS and Parkinson’s disease when I 
1 The Festival of Neuroscience, the British Neuroscience Association’s biennial conference, took place at 
the Barbican in April 2013. Alongside the scientific programme was the public programme ‘Wonder: Art 
and Science on the Brain’. The event attracted nearly 2,000 delegates and over 5,000 members of the public. 
See the BNA website at www.bna.org.uk/BNA2013-festival-of-neuroscience.html (visited 5 August 2014).
Figure 1: Professor Tilli Tansey
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was a practising scientist. As an historian it seemed to me that this was an issue 
that we really should try to look at, to capture the reminiscences of those of you 
who were there at the very beginning, and to look at how this field has changed 
in the past 40 or 50 years.2 A key part of any Witness Seminar is finding a 
suitable chairman/moderator, and I’m delighted that Hugh Perry, Professor 
of Experimental Neuropathology from Southampton, has agreed to chair this 
meeting. I know you will all know him. We’re very pleased, Hugh, that you’ve 
agreed to do this and I will hand the meeting over to you. 
2 See Appendix 1 for a timeline of brain banking from 1950. 
Sharing brain samples/tissues before brain banks 
Early brain banks (c.1990)
Started by? Funded by? Where? Purpose?
Public perception of brain banking and changes with time 
Further development of brain banks
Started by? Funded by? Where? Purpose?
Technological changes, e.g. fixation, staining, storing etc.
Getting the brain faster? 




Implications and ethics 
Storage, maintenance, usage
Recruitment of donors
The increasing importance of linking brains in banks to clinical  
information during life
Disposal of unused material?
Future of brain banks
Table 1: Outline programme for ‘The Development of Brain Banks  
in the UK c.1970 – c.2010’ Witness Seminar
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Professor Hugh Perry: Thank you very much. I can only echo what Tilli has 
said – I hope that everyone will feel that this is a conversation to get behind the 
usual things that people say at meetings, an opportunity to say what you think 
is important, what you think is not important and shouldn’t be given the time 
of day. To discuss those things that you might not otherwise say in a meeting. 
Maybe we could just briefly go around the room and make sure that we do all 
know each other. I’m a mouse biologist, my brain bank is full of very small 
brains, mostly olfactory, but I have had the opportunity to get very close to 
brain banking, so that’s where I come from. 
Professor Peter Lantos: I’m Professor Emeritus of Neuropathology, retired 
happily. I worked at the Institute of Psychiatry – Maudsley Hospital for well 
over two decades. This later became the King’s Clinical Neuroscience Centre 
(Department). For most of this time I was also actively taking part in brain 
banking issues and I have not given this up even after retirement since I’m one 
of the trustees of Alzheimer’s Research UK which, as you know, considerably 
supports brain banking in this country.3 
3 The dementia research charity, Alzheimer’s Research UK (the Alzheimer’s Research Trust until 2011), 
specializes in research into the causes, prevention, treatment, and cure of dementia. See the website at www.
alzheimersresearchuk.org (visited 3 November 2014).
Figure 2: Professor Hugh Perry
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Ms Brenda Nally: I’m the outreach coordinator for the Brain Bank for Autism 
and Related Developmental Research at Oxford, which is a very new area of 
brain banking; it’s only just over four years old and I think there are some quite 
distinctive issues around the work we do.4 
Professor Margaret Esiri: I’m a neuropathologist who describes herself as semi-
retired. I’m still in Oxford where I’ve carried out most of my career and I’ve 
been interested in dementia and inflammatory diseases of the nervous system. 
More latterly, with Brenda, I’ve started the UK Brain Bank for Autism. 
Professor Paul Francis: I’m currently at King’s College London. I direct 
Brains for Dementia Research, which is an Alzheimer Society’s and Alzheimer’s 
Research UK network of UK brain banks.5 As my day job, I like to describe 
myself as a consumer of human brains. I do a lot of research on human brains, 
and have done since 1982, focused on dementia research. 
Dr Joanna Jenkinson: I’m a Neurosciences Programme Manager at the Medical 
Research Council (MRC) and, until a couple of weeks ago, I looked after brain 
banking, having taken over from Catherine Moody.
Dr Catherine Moody: I’m also a Neurosciences Programme Manager at the 
MRC, Jo’s predecessor from 2006 to 2010. The MRC set up a UK network of 
brain banks in 2009.6 I currently look after neurodegenerative diseases.
4 The Brain Bank for Autism & Related Developmental Research is part of the Thomas Willis Oxford 
Brain Collection at the University of Oxford. Funded by the Charity Autistica, it was set up in 2008 to 
research the causes of autism and the way in which the autistic brain develops and functions. See their 
website at www.brainbankforautism.org.uk/index.php (visited 6 August 2014).
5 Brains for Dementia Research is an initiative set up in 2007 to create a network of brain banks to 
promote brain donations to provide tissue for research into the causes and treatment of dementia. Funded 
by the Alzheimer’s Society and Alzheimer’s Research UK, it is based in six centres – London, Oxford, 
Newcastle, Bristol, Manchester, and Cardiff. See www.brainsfordementiaresearch.org.uk/ (visited 6 August 
2014).
6 Dr Joanna Jenkinson wrote: ‘The MRC set up the UK Brain Banks Network in 2009, an independent and 
co-ordinated national network of existing UK brain tissue resources, to manage the provision of brain tissue. It 
aims to provide operational efficiency for the benefit of donors, researchers, and future patients. Member banks 
have signed up to common standards for brain tissue banking, including donation, access and availability, 
protocols and procedures – to make it easier to find out about brain banking and to donate brain tissue. A 
further aim is to speed up the collection of tissue that is currently in short supply for research, including tissue 
from individuals unaffected by disorders of the central nervous system, as this is critical for use as a baseline for 
comparative studies.’ Note on document sent to Mr Adam Wilkinson, 13 November 2013. See also the MRC 
website at www.mrc.ac.uk/research/facilities/brain-banks/about/ (visited 6 August 2014). 
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Professor David Mann: I’m a kind of neuropathologist at Manchester. I say a kind 
of neuropathologist because I’ve never been formally trained in neuropathology 
in my entire life. I’m a kind of self-taught scientist come neuropathologist. I 
started on this game in the late seventies so I’m nearly retired: not quite semi, not 
quite fully, but on the way. I work on degenerations, Alzheimer’s, frontotemporal 
dementia, motor neuron disease, Parkinson’s, that kind of thing.
Ms Karen Shaw: I’m the nurse specialist at the Queen Square Brain Bank, a 
brain bank mainly involved with movement disorders.7 I’ve been there for about 
13 years and I’ve been asking people and talking to people about donating their 
brain for research, probably for about 16 years. 
Professor Gavin Reynolds: I started my involvement with post mortem tissues 
in Vienna in the late 1970s and spent a couple of years running the Cambridge 
Brain Bank in the early 1980s8 and carried on collecting brains in Nottingham 
for five years and subsequently have been using them up. My main interest has 
been in schizophrenia and other psychiatric disorders, but I’ve done a little work 
on Huntington’s and Alzheimer’s too.
7 The Queen Square Brain Bank for neurological disorders was established in 1984 and specializes 
in Parkinsonian movement disorders. See www.ucl.ac.uk/ion/departments/molecular/themes/
neurodegeneration/brainbank (visited 2 June 2014).
8 The Cambridge Brain Bank was established in 1975 for research into neurodegenerative disorders. See 
their website at www.cuh.org.uk/research-and-development/for-public/cambridge-brain-bank (visited 2 
June 2014). For information on the history of the Cambridge Brain Bank see Parry and Gere (2006); also 
Department of Health (2003), Chapter 26.
Figure 3: Participants at the Witness Seminar
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Professor Carol Brayne: I’m a public health physician from Cambridge and I 
became involved in brain banking as an epidemiologist around 1984 with the 
Cambridge Brain Bank and Claude Wischik,9 and working on brain donation 
from populations. I’ve been involved in brain banking ever since and particularly 
in the Cambridge City over-75s Cohort and the MRC Cognitive Function and 
Ageing study brain donation programmes.10
Dr Djordje Gveric: I’m currently manager of the Multiple Sclerosis and 
Parkinson’s Brain Bank at Imperial College.11 I started some 20 years ago with 
the then MS tissue bank at the Institute of Neurology. 
Perry: Thank you everybody. My interface with brain banking actually first 
came about because of meeting Margaret Esiri, which touched on two ends 
of brain banking, one historical and one where we hope to be now. In the 
historical bit we had done some experiments in rodents and had seen what 
had appeared to be inflammatory disease leading to injury to axons in the 
brain. Being a rather pragmatic sort of person, I wanted to know whether this 
could possibly be true of human brains. One of the things we immediately 
recognized was that if you’re somebody who has worked with experimental 
rodents most of your science career, getting to grips with the human brain is a 
completely different business and you really do need to work with somebody 
who knows their way around. I think this is often not appreciated by people 
outside the field. I got together with Margaret to ask whether we could look 
for axon injury in the brains of people with multiple sclerosis. Margaret said 
yes, of course we could, but we would have to get the material from different 
9 Professor Claude Wischik holds the Chair in Mental Health at the University of Aberdeen. His research 
focuses on the molecular neuropathology of Alzheimer’s disease.
10 The Cambridge City over-75s Cohort Study (CC75C) started in 1985 as a long-term study of over 2,600 
men and women aged 75 and above. This has investigated, among other topics, the prevalence, incidence, 
and risk factors for cognitive decline and dementia; patterns of cognitive change; neuropsychology, 
depression; and the brain donor programme. See the study website at www.cc75c.group.cam.ac.uk (visited 
2 June 2014). The MRC Cognitive Function and Ageing Studies (CFAS) are longitudinal studies in several 
centres across the UK, which look at ageing and health and cognitive function in older people. A brain 
donation programme is managed in each location and has had more than 500 donations. See the website at 
www.cfas.ac.uk (visited 2 June 2014), and, for a discussion of the neuropathology from the donated brains, 
see Wharton et al. (2011); see also Neuropathology Group of the Medical Research Council Cognitive 
Function and Ageing Study (MRC CFAS) (2001); Xuereb et al. (2000). 
11 The Multiple Sclerosis and Parkinson’s Tissue Bank, based at Imperial College London, is a national 
tissue bank that collects tissue from individuals with MS, Parkinson’s, and other neurological conditions. 
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places and some was in the Radcliffe Infirmary and some was also from a 
place I had never heard of – the Corsellis Collection at Runwell in Essex.12 I 
wondered: ‘How on earth do all these brains end up in a place called Runwell 
in Essex?’ I’m sure Margaret will enlighten us in a little while. We published 
what I think is still a very interesting paper; I like to think of it as sort of a 
landmark paper.13 I’m not going to go into all the details but it was about 
axon injury in multiple sclerosis and it was really a great way to start working 
together on human neuropathology. But at the same time I was in a new 
department for me, the Department of Pharmacology, in Oxford, and I got 
talking to Margaret again and discovered that the OPTIMA project (Oxford 
Project to Investigate Memory and Ageing) was really just beginning to gather 
pace in the early 1990s. This was trying to do something that we are talking 
a lot about right now, which is: how do we map clinical phenotype onto 
neuropathology?14 Remarkably, when we did the first study together, when we 
talked about axon injury in multiple sclerosis, we didn’t really think about the 
fact that these brains might have come from people with lots of different types 
of MS; we just wanted enough MS lesions so we could get to grips with what 
we thought was going on. I think this was an interesting separation between 
the two approaches: one was the collection of brains where the phenotype, 
the clinical phenotype, didn’t seem to be important, and maybe Margaret will 
correct me on this; and then at the same time this new approach of OPTIMA. 
The MRC Cognitive Function and Ageing Study (CFAS) of course started in 
the same year, 1988, so it was an idea that mapping clinical symptoms and 
pathology had to be brought closer together rather than ‘this was a clinical 
disease’. Maybe, Margaret, you would comment on the Corsellis collection?
Esiri: Peter may know actually more about the Corsellis collection. 
12 Professor John (Nick) Corsellis (1915–1994), a consultant neuropathologist, set up a brain collection at 
Runwell Hospital in Essex in the 1950s. It is now the largest brain collection in Europe with over 6,000 
specimens, a large number of which came from people who suffered from psychiatric and neurodegenerative 
illnesses. The collection is now managed by West London Mental Health NHS Trust. For a brief history 
see Department of Health (2003), Chapter 33. See also pages 10 and 15 and further biographical details of 
Nick Corsellis on page 92.
13 Ferguson et al. (1997).
14 The OPTIMA project was set up in 1988 to study the causes of dementia, especially Alzheimer’s disease. 
It also aimed to investigate changes that occur in the ageing brain, ways of diagnosing Alzheimer’s disease 
and other dementias, and how onset might be prevented or delayed. See www.medsci.ox.ac.uk/optima 
(visited 23 September 2014).
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Lantos: I would like to make a point at the beginning, which may be pertinent 
to later discussion, that there is a difference between collecting brains and brain 
banking. Collecting brains for diagnostic purposes goes back a very long time, 
you can argue to the beginning of medical research. If one has brains for one’s 
own interest, preserving material for one’s own research, and research with 
immediate collaborators, that is collecting brains. On the other hand, brain 
banking is something completely different: preserving tissues with specific 
aims and distributing tissues to the scientific community without necessarily 
the locals being involved, but they usually are. So I’m not sure whether the 
Corsellis collection started as a brain bank or whether Nick Corsellis, who was 
interested in certain neurodegenerative processes, including dementia, had a 
fantastic collection of brains, which he was generous enough to distribute to 
other people as well.15 But, for instance at the Middlesex Hospital, which exists 
no more, we had a brain collection but it was not a brain bank. We kept brains 
that were of some interest to us and our immediate collaborators. So brain 
banking is somewhat different. 
Esiri: Yes, I agree it’s somewhat different. I think there is a definite link between 
the two – they’re not totally different activities – and I think brain banking 
15 See note 12.
Figure 4: Professor Peter Lantos
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has the form that it has now developed into because of the way in which our 
understanding of disease has developed. So in Oxford in the seventeenth century 
we had Thomas Willis, a physician who saw people with strokes and things like 
that and realised that what was wrong with them was that something was wrong 
with their brains. But that was just a sort of gross beginning of understanding 
neuropathology.
Lantos: There was Leonardo before, so you can argue that it goes back further. 
And there were Egyptian surgeons who interfered with the brain so it is very 
difficult to draw a line that distinguishes interest in the brain, from collecting 
brains and brain banking. 
Esiri: Brain banking involves studying the disease and then moving on. But I 
think over our professional lifetimes what has happened is that we’ve gone on 
from being able to link pathology in the brain with a clinical symptomatology in 
some detail. We’ve done that but the techniques that have been developed have 
allowed much, much more than just looking down the microscope and seeing 
what the features are that characterize a particular disease on a microscopic level. 
The thing for me that really turned me to brain banking was a paper that was 
published by David Bowen, a biochemist at Queen Square, in the mid-1970s in 
Figure: 5 Professor Margaret Esiri
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Brain.16 He showed that you could detect differences in the activity of enzymes in 
the brain in post mortem material and show that in a particular condition there 
were differences in these enzymes from controls. Paul will know a lot more about 
this than I do, but it just amazed me that you could actually take post mortem 
brain tissue and find that there was still meaningful enzyme activity there. So I 
thought to myself: ‘Well, it doesn’t make sense to be always putting every brain 
we receive into formalin if some of this tissue could be studied by a biochemist 
like David Bowen, who may be able to find out more about these diseases.’ 
So that’s really what started me off on brain banking, and two or three years 
afterwards, a gerontologist in Oxford became interested in Alzheimer’s disease 
and wanted to study it with me. As a neuropathologist you need tame clinicians 
who are interested in the same condition as you are because you can’t get direct 
access to the tissue – it only comes through the process of being looked after 
and having a clinician. Gordon Wilcock was this clinician, at the time he was 
a senior registrar but he soon enough became a consultant and he had beds in 
the Radcliffe Infirmary where he had everybody tested to see whether they had 
dementia or not.17 When they died he asked their relatives if we could study 
their brains, so we got very quickly a very, very good series of cases that were, 
or were not, demented on the gerontology wards. That was a huge boost to our 
opportunity to study this aspect of things.
Perry: So was this the first time brains were not just put in formalin and people 
started taking frozen samples? Is this the beginning of freezing brains?
Esiri: Well, it was in Oxford. I don’t know whether it may have been done 
earlier in other places. 
Reynolds: Yes, I think it was at much the same time that Ted Bird in Cambridge 
had done it.18 I think maybe I should also make the point that almost all brain 
16 Bowen et al. (1977a and b). David Bowen (1940–2011) joined the department of Neurochemistry at 
the Institute of Neurology, Queen Square in 1970. His research focused on the neurochemical basis of 
Alzheimer’s disease. See page 91 for further biographical details. 
17 Dr Gordon Wilcock was Consultant Physician to the Departments of Geriatric and General Medicine 
from 1976 to 1984 and Clinical Lecturer in Geriatric and General Medicine at the University of Oxford 
from 1978 to 1984, when he was appointed Professor of Care of the Elderly at the University of Bristol. See, 
for example, Wilcock and Esiri (1982). 
18 Dr Ted (Edward) Bird was an MRC Clinical Scientist in the MRC Neurochemical Pharmacology Unit, 
headed by Dr Leslie Iversen, and an Honorary Consultant in the Department of Neurosurgery and Neurology 
at Addenbrooke’s Hospital, Cambridge. His research focused on the neurochemical factors of Huntington’s 
disease. He moved to the USA in 1978 and set up the the Harvard Brain Tissue Resource Center (HBTRC). 
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banks came out of personal collections and I think that is what happened with 
Ted Bird. He was interested in understanding Huntington’s disease and set 
up what was essentially a nationwide collection scheme in order to generate 
as many Huntington’s brains as he could get hold of. That probably was the 
first time that Huntington’s brains were investigated in a chemical manner 
rather than in a classic neuropathological manner, and it was very successful 
in understanding the neurotransmitter pathology of the disorder. It was from 
that nationwide collection that enabled the Cambridge Brain Bank to develop 
nationwide collecting of schizophrenia samples and also Alzheimer samples. 
Brayne: I was just going to add to that, the sequence of Bird and Iversen and 
then Wischik, in terms of taking that protocol, which was half frozen, half 
fixed.19 Bronwyn Parry, in a previous Wellcome award, has documented that 
19 Bird and Iversen (1974); Lai et al. (1995).
Figure 6: Professor Gavin Reynolds
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history in her papers in collaboration with CFAS.20 She did a detailed embedded 
social science Wellcome-funded project, which led eventually to the Mind Over 
Matter exhibition.21 
Lantos: Establishing seniority of brain banks, one of the oldest in London was 
probably at the Maudsley Hospital. The credit should go to Professor Alfred 
Meyer, who was Professor of Neuropathology and started collecting brains with 
psychiatric diseases and later on with Creutzfeldt-Jakob disease (CJD), which 
at the time was of very little interest to the general public.22 In a way it was a 
personal collection but it later gradually became a brain bank in the sense that 
the material was distributed quite widely, including the National Institutes of 
20 Parry and Gere (2006).
21 Bronwyn Parry is Professor in Social Science, Health & Medicine at King’s College London. The Mind 
Over Matter exhibition, held at Shoreditch Town Hall, London, in October 2011, featured the identities 
and photographs of brain donors. See www.mindovermatterproject.co.uk/about.html (visited 9 June 2014), 
and further comments by Professor Carol Brayne on page 28. 
22 Alfred Meyer (1895–1990) left Germany in 1933 and worked at the laboratories at the Maudsley 
Hospital. He was appointed Professor of Neuropathology at the Institute of Psychiatry and the Bethlem 
Royal and Maudsley Hospitals in 1949. See Anon (1991).
Figure 7: Professor Carol Brayne
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Health (NIH) in Bethesda, and this work, which later was crowned with a 
Nobel Prize, used some of the material provided by the Maudsley Hospital.23 
So that’s one of the very old brain banks. The other that Margaret mentioned is 
the Runwell collection started by Nick Corsellis, I think, in the early 1950s. He 
got involved in dementias, particularly Alzheimer’s disease and also in dementia 
pugilistica or boxer’s dementia.24 This brain collection was extremely useful and 
many other people benefited from it. But if I go back just for a minute to the 
Maudsley, I should have mentioned another very interesting, quite unique, part 
of that collection – brains of patients who had a lobotomy. What’s happened to 
those brains now, which is of great historical interest, I don’t know, but we could 
find out. So that collection goes back really to the early 1940s. 
Mann: I suppose my interest and experience of brain banking came through 
an entirely different route. I got into it essentially as a fairly raw PhD student 
and postdoctoral work in the sense that I graduated in zoology of all things for 
my sins and did a PhD in a pathology department, which just happened to 
be a project that related to some element of nervous system anatomy. It was a 
question that some people who are old like me might even remember. There 
were a few papers about polyploidy in the nervous system that my supervisor, 
Peter Yates, thought was an interesting thing for a PhD student to look at,25 and 
this project was designated to me.26 But, in fact, after about 12 months it turned 
out to be a complete load of nonsense and I was stuck in the middle of a PhD 
looking for something to do.
Perry: Not the first, I suspect. 
Mann: So I turned my attention to this rather dark and gloomy room in the 
pathology department at Manchester University, which had all these jars and 
buckets with pickled brains in them, and thought: ‘Well, there must be something 
23 In 1966 Elizabeth Beck, a neuroscientist at the Maudsley Hospital, provided the American virologist 
Carleton Gajdusek and his colleagues at the NIH with a sample of a brain biopsy of a patient with CJD; 
this was used to inoculate a chimpanzee that later developed a prion disease. In 1976 Gajdusek was jointly 
awarded (with Baruch S. Blumberg) the Nobel Prize for his work on kuru and CJD, showing that prion 
diseases were transmissible infections.
24 See Corsellis, Bruton and Freeman-Browne (1973); Corsellis (1989).
25 Peter Yates (1921–2001) was Professor of Neuropathology at the University of Manchester Medical 
School and Consultant Neuropathologist at the Manchester Royal Infirmary. See Herman and Lapham 
(1968, 1969); Lapham (1968). 
26 Mann and Yates (1973a and b).
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interesting here to work on.’ So I rummaged through the catalogues and came 
across some really weird and wonderful disorders with names I’d never heard 
of, including something called Alzheimer’s disease. I thought: ‘Hm, this sounds 
interesting. I’ll have a look at a few glass slides of this.’ And looking at those I 
was confronted with these wonderful structures, which we still don’t understand 
even now, called plaques and tangles. I thought: ‘Good grief, what on earth 
is going on here?’ and that stimulated the interest. So I rummaged through 
the collection and saw what else there was, and there were some odd things 
like motor neuron disease and Parkinson’s, and I thought: ‘Right, we could 
do something with these for the PhD’, and that’s really how the Manchester 
Brain Bank originated, from sifting out material that pathologists had kept 
essentially for teaching.27 They did do research on these things – they used them 
for diagnosis and teaching obviously – but they kept them there as products of 
the pathological museum. And that turned into a research exercise.
27 Mann (1972).
Figure 8: Professor David Mann
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Perry: Who was paying for these collections? We know when anybody collects 
anything it costs an enormous amount of money. But, of course, it wasn’t that 
long ago that quite a lot of research didn’t cost that much money. 
Mann: Departmental budgets, I guess, or some nebulous income from the 
Health Service or from the university which supported diagnosis. 
Lantos: In Manchester again we talk about using, or collecting, brains for 
diagnosing purposes, which was obviously part of the departmental budget, 
but it was a different matter when we were actually advertising to obtain more 
brains well beyond the interest of the host institution, and that is brain banking. 
So even if the difference is reflected in funding, the same way as certain other 
parts of the body have been kept for a while for research, some brains had been 
kept as part of the routine diagnostic service. The funding of this was obviously 
part of the department or institute or the hospital’s budget, but once we started 
to have brains from other sources and from other parts of the country, funding 
became very important and it was necessary to obtain outside funding. When I 
was at the Middlesex Hospital, we looked at the brains – no one paid for those 
because it was our diagnostic service to do so. At the Institute of Psychiatry 
when I started a brain bank with David Marsden, then we obtained the help of 
the Medical Research Council for a very long time. In fact the MRC, I think, 
still funds the same brain bank.28
Mann: Just going back to what Margaret said, I think the impetus for me to 
collect brains locally within Manchester, working with local clinicians to recruit 
cases of Alzheimer’s disease particularly, again came through working with David 
Bowen and the cholinergic story, and not specifically at that time to do the 
initial studies on post mortem material.29 Then we were more interested, with 
Paul and David, in the product of that enzyme activity in terms of acetylcholine 
synthesis rather than assessing the cholinergic enzymic capability of the brain 
28 The MRC London Neurodegenerative Diseases Brain Bank was set up in the Department of 
Neuropathology, Institute of Psychiatry, King’s College London, in 1988 and is funded by the Medical 
Research Council. (Charles) David Marsden (1948–1998) held the chair in Neurology at the Institute of 
Psychiatry and was a consultant at the Maudsley and King’s College Hospitals from 1972 to 1987 when he 
was appointed to the chair of Clinical Neurology at the Institute of Neurology, Queen Square, a post that he 
held until 1995 when he became Dean. His research focused on neurological disorders affecting movement, 
especially Parkinson’s disease. See Quinn (2006).
29 See pages 11–12.
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in Alzheimer’s in particular.30 To be able to get brains, and to measure the rate 
and degree of acetylcholine synthesis, was a completely different kettle of fish to 
simply collecting post mortem brains and measuring relatively robust markers, 
such as choline acetyltransferase activity. But there are lots of stories there, and 
I’m sure Paul will regale you with them at some point in the afternoon. If he 
doesn’t, I will, and this will link in with the items further down the list in terms 
of post mortem delays and such like, and the experiences we had in connection 
with that study. 
Perry: So it’s obviously an interesting transition from collections to bank. 
One of the things I’m intrigued to know about is how did it feel to be a 
neuropathologist? That may sound like a slightly odd question but we know 
that in medicine there are hierarchies, people are seen as the top of the tree and 
other people less so: I would say, for example, our friends in psychiatry clearly 
feel that this is an area that is withering because young people don’t want to 
be psychiatrists any more. I think that recruitment into neuropathology is also 
a bit of a problem. How did it feel to be a neuropathologist at a time when it 
was not a discipline, but had all these techniques to hand? We can start with 
our more emeritus colleagues – it’s more how you think people perceived you 
rather than whether you were happy. Was pathology, neuropathology, seen as a 
premiere discipline?
Esiri: I think neuropathology in Oxford was quite fortunate because there 
was a lot of money put into the medical school by Lord Nuffield who made 
cars.31 One of the departments was the Nuffield Department of Surgery and 
the first Professor of Surgery that was funded by that source was Hugh Cairns, 
who was an absolutely outstanding neurosurgeon who understood completely 
the importance of neuropathology.32 So the first neuropathologist in Oxford 
was brought in by him to help him and his colleagues, other neurosurgeons, 
because they need to know what sort of a tumour something is before they can 
provide advice about how to manage it. So our main bread and butter work was 
diagnosing tumours.
30 See for example, Neary et al. (1986). 
31 William Richard Morris, Viscount Nuffield (1877–1963) was a motor manufacturer and philanthropist. 
He set up the Nuffield Foundation in 1943 to provide medical and social welfare and, from the 1950s, 
educational grants.
32 Sir Hugh Cairns (1896–1952) was appointed as the first Nuffield Professor of Surgery in Oxford in 1937. 
See Jefferson (1959).
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Perry: Do you think you were highly regarded?
Esiri: No, I don’t think we were highly regarded. We were definitely back room 
boys and girls. But it was a very comfortable back room. We had very nice 
colleagues and it worked.
Lantos: I think it depends on the actual place one is, or has been, working. There 
was a difference in the perception of neuropathology by others at the Middlesex 
Hospital and in the Institute of Psychiatry. The Middlesex Hospital where I 
started in 1968 as a Wellcome Research Fellow from Hungary for one year, with a 
generous stipend of £1,200 per annum, was expanding research into neurological 
diseases. This was made possible because one of the senior consultants was given 
an endowment of £1 million, which in 1968 was quite a lot of money. We 
called this later the ‘Biscuit Money’, since the donation was by Garfield Weston 
of Fortnum & Mason and other enterprises.33 That later became the Institute 
of Neurological Sciences, which exists now. So there was a perception that we 
need neuropathologists, and my senior colleague, Dr Helen Grant, was on the 
diagnostic side and I was working on a PhD.34 Our work was appreciated by 
the clinicians: it was not glamorous but was well thought of. At the Institute of 
Psychiatry it was different because there are the biological psychiatrists who think 
that we need brains and there are the social psychiatrists who think: ‘Well, what 
are they for?’ So at the time there was this division but obviously early on I found 
collaboration with biological psychiatrists, mainly with neuropsychiatrists and 
also old age psychiatrists. This turned into a very fruitful collaboration and these 
colleagues appreciated neuropathology, so I can’t complain.
Perry: Gavin and Paul, neuropathology – is it still in this back room or are you 
more front room?
Reynolds: I’m not a neuropathologist. I trained as a chemist in fact, a biochemist, 
and then a pharmacologist. I think that I, with David and Paul, probably share 
the view that we did our best to work closely with neuropathologists and 
33 Williard Garfield Weston (1898–1978) was a Canadian businessman and philanthropist. He moved to 
the UK in 1932 and established Associated British Foods in 1935 and in 1958 set up the Garfield Weston 
Foundation, a grant-making trust that supports organizations and activities in the arts, education, youth, 
health, community, environment, religion, and welfare across the UK.
34 Dr Helen Grant (1922–2012) was a consultant neuropathologist at the Middlesex Hospital and later at 
the Charing Cross Hospital. During the 1980s and 1990s she was one of the first scientists to warn of the 
dangers of BSE crossing from animals to humans; she also warned of the danger of brain damage caused by 
boxing. See Lantos (2012).
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other general pathologists, but we were often seen, I think, as sort of eccentric 
scavengers. In Cambridge I, or my technician, used to go downstairs to the 
mortuary and negotiate over brains. This was, of course, in the days when this 
sort of thing was rather more possible. We could discuss the opportunity that 
we might be able to provide some pathological feedback in exchange for having 
these brains that we could then bank and formally provide for those who in the 
future wished to withdraw. But it was very much a sort of negotiated process, 
wasn’t it? 
Francis: Yes. I came from a background working on chicken brain so, like 
Hugh, I had an even bigger journey when I came to human brain. When I 
moved to Queen Square in 1982 to work with David Bowen,35 I very quickly 
worked out that there were helpful neuropathologists and there were probably 
those who were less likely to be useful to the sort of things we were doing. 
The Department of Neurochemistry at Queen Square was, I think, set up in 
1970, and Alan Davison was the chair.36 He brought together people who were 
35 See note 16.
36 Alan Davison (1925–1993) was Professor of Neurochemistry and Chair of the Department of 
Neurochemistry at the Institute of Neurology, Queen Square, from 1971 until his retirement in 1990. 
Figure 9: Professor Paul Francis 
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interested in studying chemistry of the brain, multiple sclerosis, Alzheimer’s 
disease, and other forms of dementia. David Bowen was there, Louise Cuzner 
was particularly focusing, with Alan Davison, on MS.37 I think the first studies 
had perhaps happened in the late 1960s. There’s a name that comes back to me 
and I wonder if Peter or Margaret know this, Korey, who I think may have done 
some of the early chemical studies on the brain.38 So the idea that you could 
use frozen tissue and do chemistry was something and then perhaps going back 
to Arvid Carlsson and looking at the monoamines.39 I think that would be the 
time of things. The Department of Neurochemistry at Queen Square was then 
set up to try and take this forward. Of course, one of the imperatives was that, 
in addition to studying animal models, you could actually have human tissue 
to study – frozen human tissue that would be suitable. As Margaret says, I 
think in terms of Alzheimer’s disease the key studies were in the mid-1970s – 
Newcastle, London, and Edinburgh would be the main ones – actually looking 
at enzyme activity in the brain. Now, what you needed was a neuropathologist 
who wasn’t going to slip the whole of the brain into formalin. You needed 
someone who was amenable to actually not do that, and fortunately there 
were people. Nick Corsellis was, I think, the supplier for David’s studies – I 
checked with Margaret on this – and he was the supplier of material for the 
1976/77 papers that David did.40 I don’t know who supplied Peter Davis from 
Edinburgh;41 Newcastle had its own sort of brain collection at the time. But 
obviously there were people who were prepared to listen to you, people like 
Gavin and David. 
37 Louise Cuzner is Emeritus Professor of Neurochemistry at the Institute of Neurology. 
38 Saul Korey (1918–1963) was Professor of Neurology at the Albert Einstein College of Medicine of 
Yeshiva University from 1955, where he was a pioneer in the field of neurochemistry and Alzheimer’s 
disease. See Scheinberg (1964).
39 Professor Arvid Carlsson (b. 1923) is a Swedish pharmacologist best known for his research on the 
neurotransmitter dopamine. He was jointly awarded (with Paul Greengard and Eric Kandel) the Nobel 
Prize in Physiology or Medicine in 2000 ‘for their discoveries concerning signal transduction in the nervous 
system’. See www.nobelprize.org/nobel_prizes/medicine/laureates/2000/carlsson-autobio.html (visited 9 
June 2014).
40 Bowen et al. (1976; 1977a and b).
41 Dr Peter Davis joined the Medical Research Council’s Brain Metabolism Unit in Edinburgh in 1974 
where his research focused on Alzheimer’s disease. In 1977 he moved to Albert Einstein College of Medicine, 
New York, as Professor of Pathology and Neuroscience, and in 2006 was appointed Director of the Litwin-
Zucker Research Center for the Study of Alzheimer’s disease at the Feinstein Institute for Medical Research.
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I think around the same time, as a slight tangent to this, when I first came 
to work with David Mann, we’d done a lot of work on post mortem brain 
but we wanted to be sure how representative this was. So we had colleagues 
in Manchester who were undertaking neurosurgical biopsies of people with 
dementia for diagnostic purposes, and we said: ‘Please can we have some of 
that tissue to do some chemistry?’ because, of course, from a living person 
the amounts taken were tiny but we only needed a small amount. And you 
know biopsies were done; they were done in the USA as well for a short time. 
I remember a paper that David did comparing people who had had a biopsy 
in life with follow-up neuropathology looking at the changes.42 We also were 
able to access neurosurgical samples from Queen Square so we were in the 
right place at the right time and we had something which resembled control 
material for the neurosurgical biopsies of people with dementia. So I think 
all of this came together and it was probably a slow burn but eventually we 
had a large collection of people in strategic areas. Margaret Esiri and David 
Mann particularly were most helpful in helping us to get the sort of tissue we 
needed to do these studies: a variety of tissue, relatively standardized tissue that 
could be used and applied to a particular question. I think that’s where I came 
in. I pick up Peter’s point about collections versus brain banking, that brain 
banking was really probably mostly driven by the need for chemical analysis of 
the brain rather than neuropathological analysis of the brain which could be 
done on collections. People would say: ‘Well, this case is a bit different to that 
case, which is a bit different to that case, which is a bit different to that case.’ 
There was a big distinction at the time in Alzheimer’s research between presenile 
dementia and late-onset Alzheimer’s disease. People thought they were different 
diseases but eventually chemistry and the pathology showed that actually they 
were very, very similar. So I think the whole field was dragged along and brain 
banks were probably often driven by people like us asking for frozen tissue – 
you didn’t need one case, you needed ten cases maybe.
Perry: That’s potentially very interesting because, of course, the demands now 
of modern techniques are also for fresher, better preserved, frozen tissues for 
study of the transcriptome, proteome, lipidome, and so forth. Again, there’s a 
slightly different pressure but it’s interesting that chemistry was driving it rather 
than simply detection of pathology.
42 Professor David Mann added: ‘ …looking at the same plaque and tangle pathology and comparing 
the amounts of them at the two time points (Mann et al. (1988)).’ Email to Ms Caroline Overy, 
14 October 2014.
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Mann: I’ll follow up from Paul. Having done the biopsy work myself, I think 
one of the really important issues that came out of it was that, not only was 
the basic enzyme responsible for making acetylcholine defective in Alzheimer’s 
disease, but also what was there was incapable of making the right levels of 
acetylcholine. We wanted really to follow this up in a large number of cases, 
and getting cell biopsies and the right amount of material from cell biopsy was 
really not easy to achieve. So we looked and said: ‘How can we use post mortem 
material to answer that question?’ In Manchester we set up a system whereby we 
obtained pre-mortem consent to brain recovery with the relatives fully involved 
when the whole situation was explained to them. They gave their agreement 
that we could obtain the brain tissues as soon as the patient died, so we weren’t 
hidebound by this ‘green form’ paraphernalia that so besets us nowadays.43 And 
the net effect of that was that I would make journeys across Manchester at 2 
o’clock in the morning to Prestwich Hospital, a big psychiatric hospital at the 
time, where many of the patients were resident. There, I would meet the local 
mortician and we would extract the contents of the head from these individuals 
who had kindly agreed to donate the tissues for research, and I would hot foot, 
literally, across Manchester back to the University of Manchester laboratories, 
where we would dissect the brain and put it into these wonderful containers 
that David and Paul had devised, which contained preservative fluids.44 The 
next day the brain would find its way, courtesy of British Rail, down to Queen 
Square, and Paul will love to tell the tale that I would ring him up at some 
unearthly time in the day or night and say in my best Yorkshire voice: ‘Hello 
Paul. There’s a brain on a train for you.’ [Laughter] And really, as Paul says, it was 
the chemistry that drove the need not only to collect brains, but to collect brains 
of better quality than those you could simply get hold of from pathological 
archives, where everything had just been stuck willy-nilly into preservative. It 
was a rather surreal experience carrying really warm brains across a city at 2 
o’clock in the morning. 
Lantos: Just to redress the balance between biochemistry and other investigations, 
I think the key was really the short post mortem delay and the collection of the 
material soon after the patient died, not only for biochemistry but for other 
43 The ‘green form’ is the Registrar’s Certificate for Burial or Cremation. See comments by Joanna Jenkinson 
on page 51. 
44 Professor Paul Francis wrote: ‘These were large plastic “cool-boxes” such as you would use for a picnic and 
inside there were “hors d’oeuvres” trays with lids into which dissected slices of brains were put. Each sample 
was in physiological buffer.’ Email to Ms Caroline Overy, 5 November 2014.
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investigations as well, since one driving force was the development of various 
investigative techniques. One example is electron microscopy because we 
shouldn’t forget that the first major discoveries of modern Alzheimer’s research 
were achieved by morphology; it was electron microscopy which established that 
the neurofibrillary tangle is composed of paired helical filaments. Again, it was 
electron microscopy that revealed that subacute sclerosing panencephalitis (SSPE) 
is caused by a virus. So it’s not only biochemistry that was a driving force to have 
good quality tissues for examination but also other techniques. So in the 1970s, 
or even much earlier, we experienced an era in which brain research expanded 
enormously, and within a couple of decades we learned more about the function, 
structure of the brain, and its diseases than during the previous centuries. That really 
was the force to have the tissues for as wide-ranging investigations as possible. In 
addition to traditional formalin fixation for histology, different methods of tissue 
preservation were necessary for neurochemistry, later immunohistochemistry, 
electron microscopy, and it goes on to molecular biology and genetics. So 
the driving force for brain banking is not only neuropathology, although it is 
the keystone in this whole edifice, but also the expanding investigations, the 
technology which has developed so enormously and so rapidly.
Perry: I’m very interested in that, so there are the drivers for more brain tissue. 
I’m also interested in what you thought the public thought about the work 
and we’ll come to this again later when we think of our newer brain banking 
activities. I’m interested in that period of the 1970s and 1980s. What did 
the person in the street think about people studying brains? Was this really 
something that was acceptable or not?
Mann: I think actually it was not in the public perception until the Alder Hey 
story broke and then the stuff really did hit the fan at that time.45 That really did 
impact upon brain collections and brain donations. I think, by and large, people 
had an understanding of why it was necessary to collect brains and were happy 
to participate in that process, but with the Alder Hey scandal, the whole notion 
of pathologists became people who kept things in cellars and dark rooms. We 
were tarnished badly by the whole business.
45 The Alder Hey story broke in 1999 with the report that a large number of hearts, organs, and fetuses 
had been retained without consent at the Alder Hey Children’s Hospital in Liverpool. The subsequent 
investigation and publication of the Redfern Inquiry in 2001 led to recommendations for an independent 
commission to oversee cataloguing and return of 105,000 organs retained by hospitals in England, new 
laws on informed consent, and a review of the Coroner’s System (The Royal Liverpool Children’s Inquiry 
Report (2001)).
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Perry: Since you were there at the time before Alder Hey, before that came to 
the press, was it benign? Was it simply not in people’s consciousness or did they 
think it was okay, or satisfactory? What was the general feeling?
Esiri: I think it was to do with the fact that people held medical professionals 
in high regard, and if a post mortem was requested by a clinician who had 
looked after somebody in life, the relatives were very inclined to say ‘yes’. If that 
clinician said: ‘This is going to help us to understand this disease’ the relatives 
hardly ever said ‘no’. That held really until, as David says, the time when the 
Alder Hey problems arose. I think before that, because the imaging had been 
progressing so fast, clinicians had less of a need for post mortem examinations 
because they knew more about what was going on in the brain, certainly on the 
diagnostic side, though perhaps it wasn’t so much the brain banking side that 
this applied to, but certainly the neurologists had better ideas of what was going 
on because of CT scanning. They became less likely to ask for post mortems, so 
that the post mortem rate for diagnostic purposes fell off dramatically all over 
the world because of CT scans and the fact that the neurologists were no longer 
in the dark.
Perry: There are two interesting sides to this story: one is people’s perception and 
that of the press. What did you think? When Alder Hey broke, as a pathologist, 
what did you think? ‘This is an outrage? This has been waiting to happen?’ 
Esiri: I felt very, very undermined by it. I felt the media portrayed it in the 
wrong way. I felt we were the victims of a system that involved particularly 
coroners’ post mortems, which had nothing to do with the hospital system, 
where we had what we called medical interest post mortems and that often 
contributed to the brain banking as well. That was completely different to the 
coroner system where the problem was, I think, that the coroners never really 
explicitly said what you should do with an organ after you’d examined it for 
their purposes, which was to find the cause of death. So departments ended up 
with a lot of organs that they’d taken from coroners’ cases and they didn’t know 
what to do with those organs afterwards. I don’t know exactly what was going 
on in Liverpool, but my understanding was that these organs were retained 
because the pathologists felt that there was something valuable to be gained 
from studying them, but they needed funding to be able to do those studies, 
which should have been provided by Liverpool University and that funding 
hadn’t been forthcoming so those organs had just been sitting around waiting 
to be studied. 
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Perry: The impact on you was one of betrayal in some sense?
Esiri: Yes, absolutely. There was nothing that one could do about it. I remember 
going to somebody who had quite a lot to do with television productions and 
saying: ‘How can we change this understanding? It’s completely misleading; the 
media coverage has been completely misleading.’ He said: ‘Well, the only way 
that you could do it would be if you could have a patient who had a disease, had 
been part of a film while they were alive, and then you told the audience why it 
was valuable to look at the brain’, and this would have to come into a television 
programme or something.46 It was impossible. 
Perry: It’s a bit hard to plan among your colleagues. 
Reynolds: In Cambridge we were picking up many of the brains through 
coroners’ cases, particularly psychiatric cases where there were no clear next of 
kin. The coroners were often very positive about this; they saw that they were 
responsible for these cases; they were in lieu of next of kin and they actively 
supported the collection of psychiatric cases. In particular I think that the 
Depression Brain Bank or collection in London that was run by Roger Horton, 
had a very close link with the local coroners who were extremely supportive of 
their collection scheme.47 
Perry: How did it affect you personally when all this happened? I think this is 
one of the interesting aspects because we can read about what the newspapers 
thought all the time but we never hear the voice of the people who were actually 
affected as a consequence of what happened in the newspapers. What was your 
feeling?
Reynolds: Fortunately I was not directly brain banking when Alder Hey broke.
Perry: But you were using human tissues? 
Reynolds: I became very, very nervous about using human tissues and there 
was in fact some work we’d done with a paediatric pathologist where we had 
some paediatric brain tissues. That had provided us with some very interesting 
information regarding brain development. I have not published that really 
46 See comments by Professor Carol Brayne on page 28. 
47 Roger Horton was appointed Lecturer in the Department of Pharmacology at St George’s Hospital 
Medical School in 1979, rising to Professor of Neuropharmacology in 1998 and Vice-principal from 2000 
to 2007. He collected brain samples for research on suicide and depression from 1984 until the mid-1990s.
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because I felt very nervous and I wasn’t absolutely sure where exactly the 
permissions had come from for those brains because they were collected by 
somebody else so I couldn’t check.
Perry: But you felt the public pressure was enough to make you hesitant about 
carrying on this work?
Reynolds: Absolutely, yes.
Perry: So it was pretty unpleasant.
Reynolds: It is worrying. And yet, as Margaret says, where we have been able 
to inform and educate the public in general or patient groups and carer groups, 
we’ve had enormous support for brain collection. In Cambridge we had a 
prospective Huntington’s disease brain collection scheme that was initiated in 
the early 1980s. That was a slow process but it had a lot of support from the 
Huntington’s disease charity, and the same is true for other disorders, Parkinson’s 
disease in particular of course.
Brayne: I was just going to mention the prospective agreement by individuals 
during life. We started the Cambridge City over-75s Cohort Programme, which 
was a population study with participants who prospectively gave their intention 
to donate tissue, in Cambridge in about 1987/88, and then in CFAS a little 
later.48 We had that programme running during the Alder Hey media blitz as 
it were, and we experienced mostly positive responses to the brain donation 
programme within both studies and didn’t really see much of a blip, because 
we had established a relationship of trust with our respondents. So that I think 
there were streams within society where people did feel that things were okay; I 
think we only lost one or two brains because of Alder Hey. 
Perry: That is a very interesting issue. As long as you have the right 
communication, information, and relationship with the people who are going 
to be your donors, or prospective donors, then you can preserve the trust. 
Whereas the sort of thing Margaret was saying, if you’re just on the receiving 
end, it must be more uncertain.
Brayne: Finding things out afterwards is a problem. The reason why we 
introduced the declaration of intent to donate brain tissue at post mortem to 
the prospective population with the liaison nurse was because people in our 
team began to feel uncomfortable about the fact that we were following people. 
48 See note 10.
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We were following our respondents and we wanted their brains and they didn’t 
know that we wanted their brains. That was how the programme of going to 
people to talk carefully beforehand emerged for our population-based studies.49 
Before that we had lists in mortuaries and it was on spec. If they happened 
to come through to a post mortem, if the physicians were asking for a post 
mortem, we might get the brain as part of that post mortem process because it 
was covered by the rather broad consent forms at the time, for the purposes of 
research, but it was a very small section. So we had that in place in a major way; 
we did a lot of activity to try and capture people who came through the hospital 
system and the mortuary, but people weren’t coming through that way and our 
team felt uncomfortable. So we then went to the Ethics Committee and they 
said: ‘We’ve never handled anything like this before’ and we had to create the 
process in the late 1980s. Just to say, the Wellcome-funded Mind Over Matter 
project, many years later of course, did exactly what Margaret would have loved 
at the time, which was to interview our brain donors who have now given their 
brain tissue. So we now have the images and the voices of our brain donors and 
their reflections on their lives, and we have their brains as well.50
Lantos: Going back to Alder Hey, that was a very regrettable incident and it 
became more so because it was heavily politicized. We didn’t have any problems 
with brain donations because we had an obviously dedicated cohort of patients 
and their relatives. But against that there has been always a problem with post 
mortems in this country – what they are for. If I may, I wish to say something 
on a more general note. The British public rightly expects the delivery of cure 
and therapies of all diseases but at the same time objects to post mortems, 
protests against animal experiments, and is suspicious of genetic work. This 
attitude doesn’t bode very well for medical research. When I started to work in 
this country, I was surprised that one had to ask permission for a post mortem 
because in the country where I was trained, Hungary, one had to ask permission 
not to have post mortems because all the patients who died in university 
hospitals and clinics came for post mortem. The relatives were informed that 
post mortem is part of medical learning and training. At the time, of course, 
we did not use the term medical audit. So the post mortem rate at the time was 
around 90 per cent and when I came here I was amazed to find that it was, even 
in the early 1970s, around 20 per cent. So that is the background to why it is 
quite often difficult to obtain tissues from various diseases.
49 See Barnes et al. (2005).
50 See page 14, note 21 and page 26. 
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Mann: One aspect of the Alder Hey event impacted upon the number of 
donations. We had a small blip, but that quickly recovered, as Margaret and 
Carol said, through trust with the people that you’re working with. I think 
the most savage aspect that hit us was the Isaacs Enquiry.51 This related to the 
brain of a patient in Manchester by the name of Isaacs whose spouse wanted 
to recover the tissues that had been obtained through the coroner’s system for 
appropriate funeral arrangements, and the brain could not be found. This 
created a huge scandal both locally and nationally, and we were descended upon 
by the rottweilers of the Department of Health – very officious people who 
went through everything that we did with an absolute fine-tooth comb several 
times. At the end of it we were able to assure them, firstly that we had had no 
part in the retrieval of this particular brain but also, in a sense it was a bit of a 
double-edged sword, they could see really that how we did things was in their 
words ‘exemplary’, so actually it paradoxically came out in our favour. But it 
wasn’t a very pleasant experience getting the Men from the Ministry down on 
you, who had no real conception of what brain banking was about and what 
brain research was about and the need for post mortems. They were just looking 
at it from the element of ‘here’s a scandal and how deep does it go?’
Perry: Seth Love has just joined us.52 We’re talking about Alder Hey and its 
impacts: whether individuals involved in pathology personally felt threatened 
or betrayed, as Margaret described, or anxious or whatever. 
Professor Seth Love: I had an interesting experience in that I have responsibility 
for two brain banks or two brain archives. In the NHS Department of 
Neuropathology in Bristol we have an archive of brains we have retained over 
many years and have come through a range of sources, hospital autopsies, 
coroners’ autopsies, a few medicolegal brains; and then a brain bank that is 
the South West Dementia Brain Bank. From the contrast in relation to what 
happened to the two collections I think you can learn something. We have 
never had any problem at all in relation to the South West Dementia Brain 
Bank; we’ve had an increasing number of donations year on year irrespective 
of events like Alder Hey and the Isaacs brain retention. I think the people 
who donate brains often initiate the donation process. They have a very clear 
51 The Isaacs Enquiry investigated the events and procedures following the death of Mr Cyril Isaacs in 1987, 
and the removal and retention of his organs after the post mortem at Prestwich Hospital mortuary. The 
report was published in 2003; see Department of Health (2003). 
52 Professor Seth Love became the Director of the MRC-funded UK Brain Banks Network in 2013, 
succeeding Professor James Ironside. 
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understanding of the purpose of the donation and the sorts of good to which 
the tissue may be put and they have a one-to-one relation with the brain bank 
in terms of discussions, transferring paperwork, and recording all of that sort 
of information.
In contrast, the situation relating to the retention of brains in the hospital 
archive was much more problematic. I had several interviews with families who 
hadn’t been aware that tissue had been retained, although they’d signed consent 
forms at the time. What happens at Frenchay Hospital is that most of the 
brains don’t derive from autopsies that we ourselves do. A general pathologist 
in Taunton or Yeovil or Gloucester will do an autopsy and will want the brain 
examined. He will send it to us and we will examine the brain and send out 
a report. We aren’t primarily responsible for obtaining the consent and for 
having the related discussion with the families. We’re often also not directly 
the people who liaise with the coroners or with the Crown Prosecution Service. 
So we have a situation where there are lots of different authorities involved in 
communicating, in obtaining permission, and in keeping documentary records 
of consent. And there are several different legal authorities involved in the 
brain retention process, particularly when a criminal prosecution is involved. 
Finally, there’s often much less understanding amongst the next of kin as to why 
Figure 10: Professor Seth Love 
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this is all happening; they don’t want an autopsy but the coroner has insisted 
on it, they are not clear why the brain is being kept or why it’s being sent 
elsewhere for specialist examination. It’s under those circumstances that you 
get problems. What we need is something more brain bank-like where there’s 
direct communication between the family and the neuropathology service, and 
a single point of responsibility for advising on all aspects of the process.
Perry: I’ll come back to the good bits that I think came out of Alder Hey but 
personally what did you feel when the press and public almost took to the 
streets about this? Did you feel threatened? Did you think it was worrying? 
Love: I didn’t feel threatened. I felt hurt sometimes because you have been doing 
the very best that you can: (i) for the families in terms of trying to diagnose 
things, particularly if there are genetic implications; (ii) for the coroner; (iii) for 
your pathology colleagues. You haven’t had any responsibility for the things 
that have gone wrong and yet you feel you’re being blamed. So I felt hurt, not 
threatened.
Perry: So tarred with the same brush? 
Love: Tarred with the same brush, yes. 
Perry: Brenda, you deal with children, or potential donors of younger ages. Do 
you think Alder Hey still leaves a trace behind? 
Nally: I’m not sure that neuropathology of autism, which is really very new in 
the UK – it’s been developed just in the last five years – has much resonance for 
families with people with autism and people themselves who have autism, with 
what happened at Alder Hey and Bristol.53 I think it’s not been such an issue for 
them. I think that they have doubted the value of this area of research partly 
because of very different perceptions of autism and attitudes to autism from 
the whole range of other diseases, which are under investigation through brain 
banking and neuropathology. I think that’s because people who experience 
autism as a lifelong experience don’t feel that they have a disease that ideally 
would be eradicated or where causes could be identified and lead to some form 
of cure; they have suspicions about this whole area of research because they feel 
it undervalues the people who have autism as an intrinsic part of themselves. 
That’s a very strong body of opinion, which particularly people on the wide 
53 The Alder Hey scandal was immediately preceded by a scandal at Bristol Royal Infirmary when the story 
broke that the hearts and other organs of 170 children had been retained without consent. See Bristol Royal 
Infirmary Inquiry (2000).
The Development of Brain Banks in the UK c.1970–c.2010
32
autism spectrum who are of high intelligence have developed and have used to 
influence the much wider autism community in the UK and other parts of the 
world. So it’s a very different set of issues from the other issues we are discussing.
Perry: You’ve just taken us into a really interesting territory. We were talking 
about dementias and diagnosis of diseases that people are pretty clear that they 
don’t want. They don’t want Alzheimer’s disease or Parkinson’s disease, they 
don’t want motor neuron disease. Some aspects of some mental disorders are 
different; I have a colleague who has bipolar disorder and he tells me ‘the good 
bits are great; the really good bits are absolutely fantastic; just a pity about the 
really bad bits’. But the trouble is that all the drugs he takes gets rid of both, 
and he doesn’t really like that so he tries to sort of titrate himself into some 
hinterland that doesn’t do him a lot of good. Is this true of other psychiatric 
diseases, that brain banking is here perceived as an intrusion in some sense, 
rather than something valuable? Do you think this is what you’ve just said about 
autism – do you think it’s something bigger than autism?
Nally: I think it is perceived as threatening by those people who experience 
autism and members of their families who emphasize the strengths associated 
with autism: the ability to focus very clearly, to think very logically, to develop 
Figure 11: Ms Brenda Nally
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special interests and special intellectual understanding and expertise because 
of the way that their brain works. I think they feel that investigation of that, 
leading to interventions to change, is a threat.
Francis: It’s interesting picking up on that. One of the big problems with brain 
banks is that we have a lot of people who have dementia in them, and we have 
very few people who don’t have dementia. This is a misconception that we’ve 
tried to correct in the sense that we’re saying to people: ‘Actually, if you don’t 
have dementia, from our perspective in Brains for Dementia Research (BDR) 
you will be making a valuable contribution to research, because we want to know 
what it is in your brain that means that you haven’t developed dementia by the 
time you die and we will, of course, use that as a comparator with people who 
do.’ So we’re valuing both people with dementia and people without dementia; 
they then understand that it doesn’t really matter: both of their brains will be 
valuable going into the brain bank. From what you’re saying about autism, and 
what you said about your colleague, perhaps the message is that we’d just like to 
understand how the autistic brain works better rather than treat it as an illness 
that needs correcting. Maybe that’s the sort of approach that we need?
Brayne: From the ageing point of view we’ve clearly had that in terms of 
trying to get the whole population, because we want to look at the complete 
relationship between the non-demented older people and those who experience 
dementia during life. So it was about understanding the brain in its entirety, and 
in the older population in our case. That was quite successful in our population 
approaches in terms of conveying that to all of our respondents and those who 
took it up, because most of the people at the time that we recruited them for 
the brain donation programme didn’t have dementia, even though many of 
them had developed it by the time they became brain donors. So it was largely 
a mixed population. 
Nally: Yes, I think we found that the efforts that we’ve made to reach the general 
population have been very successful, partly because they had no idea that 
this area of research was under way in autism. But many people now know 
about post mortem brain research into dementia so I think we’ve found that 
the general public, when it becomes aware of post mortem brain research into 
autism, is very positive about that area of research and also about what they could 
contribute in terms of control tissue. I think the issues are much more with the 
autism community in the UK and overcoming some of the misconceptions and 
fears that are still very strong there. 
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Perry: One can understand their point of view. It does seem to me that if you 
value it then you might say, ‘Well, there’s nothing wrong with us; we’re fine. We 
just happen to have a different percept of the world and we get on with our own 
lives and we don’t need you to look at us.’ How do you deal with that? 
Nally: Well, there are people who have autism who are extremely stressed and 
have very poor quality of life and whose families are in a similar position. I think 
that they all have a quite different attitude to the potential this research has to 
make a real difference to their lives and those of future generations. So it’s a 
difficult balance across a very wide spectrum.
Perry: Perhaps we are not dealing with their many different points of view.
Lantos: Can I ask a question about the Brain Bank for Autism? While I was 
still working at the Institute of Psychiatry, Tony Bailey, Consultant Child 
Psychiatrist, was interested in autism and we had some collaborative work.54 At 
the time we had quite a few brains. Is the present Brain Bank for Autism, which 
you said was started five years ago, a continuation of that or is it an entirely new 
chapter?
Esiri: The first time I met Tony Bailey he came into my office and said: ‘I want 
to start an autism brain bank and it’s going to be in Oxford.’ So, just as Gordon 
Wilcock had recruited me to be interested in old brains, Tony Bailey recruited 
me to be interested in young brains. Then Tony was trying to get some money 
from the EU and it didn’t work and so that floundered. But in the meantime 
there was an effort by this newly formed charity, Autism Speaks, as it was then, 
Autism Speaks UK, to set up this brain bank and it was particularly driven 
because there was a very generous donation that the newly formed charity had 
to decide what to do with and that’s how the decision was made that this would 
be a valuable thing to do.55 
54 Anthony Bailey has been Professor and Chair of Child and Adolescent Psychiatry in the Department 
of Psychiatry at the University of British Columbia since 2010. In Oxford he held the Cheryl and Reece 
Scott Chair of Psychiatry from 2002. His main research has focused on the neurobiological basis of autistic 
disorders. For his research with Peter Lantos see, for example, Bailey et al. (1998). 
55 Autism Speaks UK (Autistica since 2010) was established in 2004 by the philanthropist Dame Stephanie 
Shirley as the UK affiliate of the American charity Autism Speaks; the charity funds scientific research into 
the causes, diagnosis, and treatments of autism; see www.autistica.org.uk/ (visited 29 September 2014). 
The Brain Bank for Autism & Related Developmental Research, based at Oxford University, was set up in 
2008 and is funded by Autistica. See their website at www.brainbankforautism.org.uk/index.php (visited 
10 July 2014). 
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Nally: This work had already been under way in the USA for some time and 
we have worked in close partnership with the US brain bank from the outset.56
Esiri: Yes, they were about ten years ahead of us. We work extremely closely with 
the US bank and they have very similar problems to the ones we have, I think 
it’s true to say, and we’re trying to solve them between us. 
Lantos: We have talked a great deal about brains for dementia, particularly for 
Alzheimer’s disease, movement disorders, and MS. What we haven’t touched 
is the importance of brain banking in psychiatric disorders, particularly in 
schizophrenia. I know that it’s a minefield of research from every point of 
view because even clinically it’s not quite established what it is, one disease or 
more. But that’s an area of brain banking that had been started at the Institute 
of Psychiatry and that may be something which for the future is of great 
importance.
Reynolds: I can address several of these points. Certainly schizophrenia brain 
banking was established in Cambridge as well as in London and I think a lot has 
come out of that actually although there has never been much support. We’ve 
never been able to generate the sort of grass roots support that Alzheimer’s 
disease and Huntington’s and so on can, and also haven’t really generated MRC 
and Wellcome funding support. But the Americans have done rather better 
in terms of schizophrenia and major psychiatric disorder brain banking with 
the Stanley Medical Research Institute where they have had a lot of money 
thrown at the problem and they have in the past addressed that well.57 The 
other point I wanted to make really was that, around this autism discussion, 
we were touching on something that back in the 1980s and 1990s was a major 
problem, and that was the control problem. What do we do about control 
subjects? It seems to me that actually this has been at least partly addressed by 
these prospective studies and by working closely with patient and carer groups 
because one can then recruit spouses as controls. That’s been done, I think, in 
Parkinson’s disease collection as well as Huntington’s too. That had always been 
a huge problem – we never really had enough controls in the past but I think 
that’s better addressed nowadays.
56 The Autism Tissue Program (ATP) was established in 1998.
57 Stanley Medical Research Institute in Chevy Chase, Maryland, was established in 1989 to research the 
causes and treatment of schizophrenia and bipolar disorder. The brain bank was started in 1994 and from 
then until 2005 over 600 brains were collected for the research. See their website at www.stanleyresearch.
org/dnn/ (visited 3 September 2014). See also page 81 note 119.
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Perry: Karen, can I ask you to comment? You’re at the interface with potential 
donors. Does the negativity of Alder Hey ever reappear or do you think this era 
is passed? I believe you’re mostly recruiting adults. 
Shaw: Yes. When I first started doing this Alder Hey was a few years away. I 
think I started asking people in about 1996. To be honest I do not think Queen 
Square have really suffered as a result of that. You were saying that at Cambridge 
people have had a very good relationship with the Brain Bank. I’ve known a lot 
of the donors and there has been a lot of trust. I think generally people are now 
more aware because there are people in the media saying: ‘I’m going to donate 
my brain’, and I think over the years things have recovered.58
Perry: At a tertiary referral centre like Queen Square, you must get people from 
many different cultures come through the door. Are there cultural issues that 
are interesting and that we ought to think about? Tell us about your experiences 
of that.
58 The actress and president of the Parkinson’s Disease Society, Jane Asher, and the journalists Jeremy 
Paxman and John Stapleton signed up to the Parkinson’s Brain Donor Register in 2009. The former Home 
Secretary David Blunkett has pledged to donate his brain to dementia research, and the author Terry 
Pratchett, who was diagnosed with Alzheimer’s disease in 2007, has also said he will donate his brain.
Figure 12: Ms Karen Shaw, Professor Peter Lantos, and Professor Carol Brayne
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Shaw: I think I have an awareness of religious aspects and even cultural aspects. 
The Islamic faith is the one religion that’s very hesitant about it and there are 
cultural aspects around that too, and the appropriate way to approach people. 
Perry: Before the meeting we were saying that we don’t actually know what the 
cultural differences are, whether there are age differences? Is there a generation 
that is happy to do it and another generation that feels less happy? 
Shaw: Irrespective of religion?
Perry: And/or religion. There may be no interesting nuances at all; I suspect it’s 
just ‘take each person as they come’. 
Shaw: I think approaching people is a very individual thing. I usually get to 
know people a bit. If I’m at the hospital I’m usually part of the consultation and 
get to know who they are. 
Perry: We’ve talked about these diseases of movement disorders and dementia 
and so forth, and there are all these other psychiatric disorders but there are also 
paediatric disorders too. I work with two children’s charities and I know that 
the real issue, the reason we don’t understand the diseases of the nervous system, 
is nobody has ever looked at the brains of more than a few people with these 
diseases. When it comes to paediatric donation what happens? Has anyone got 
experience of doing it?
Nally: I think the earlier issues that we were looking at in terms of whether 
people have a more basic resistance to this area of research when they’re affected 
by autism are much more influential. We found on the whole that families who 
have been involved in supporting research through donation have been extremely 
positive, and particularly families of younger people who have seen that this has 
been the one positive thing they often find has come out of their very traumatic 
experience of their younger relative’s death. In the short time that the UK Brain 
Bank for Autism has existed we’ve had three young donors who have taken the 
initiative to discover that this area of research exists and made the decision that 
they want to support it through donation, and have persuaded their families 
that this is something that they would want to do. Those families have said that 
has made it very easy for them, they haven’t had a dilemma as to whether this 
is a good thing to do or not, and how might the person have felt and what they 
might have wanted, because it’s been very clear that it’s been a positive drive from 
the donor him or herself. So that’s been very useful learning for us to recognize 
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the importance of the donors themselves making that commitment and how 
much better it is for their families to then follow through, making sure their 
wishes are carried to fruition.
Mann: I think there are certainly cultural elements attached to brain donation, 
and you could perhaps go a little bit further beyond that and say there are class 
elements of brain donation. I’m sure Paul can expand more on that. 
Perry: Do you mean socio-economic class?
Mann: Yes. As we’ve developed the Brains for Dementia Research programme, we 
had to set targets as to how many recruits we needed. An estimate of how many 
people needed to be recruited was really born out of how many brains we needed 
to harvest at the end of the day. The kind of balance between brains harvested 
and numbers recruited was really based on actuarial levels of life expectancy 
according to the time in life at which people would consent to donation. When 
we started out there was an overwhelming response to the programmes about 
advertisement and education among people between the ages of 50 and 70, but 
less so with older people, mostly from what we might call ‘Guardian readers’. The 
experience of the 5 years that the programme has run so far is that the numbers 
of brains that we’ve recruited have roughly been about 50 per cent or even less, 
30 per cent maybe, of those we predicted we ought to have recruited through 
the number of people signed up to the scheme based on actuarial analysis. I 
guess the reason for that is that those people who sign up to these schemes, 
like all voluntary schemes, come from a particularly motivated background. 
They’re often motivated to do it not only because they have a personal interest 
in the illness concerned, but they have an altruistic interest. One doesn’t want to 
invoke the kind of class structure too much, but that’s how it works. Middle-class 
Guardian readers are motivated to take part in these things.59 
Perry: You might say it’s the scientists’ fault, because we communicate to a 
particular stratum of society and don’t bother to communicate to the others. Do 
you think it could be that those you describe as the ‘Guardian readers’ are those 
who understand what’s going on?
Mann: I don’t think it’s a case of not bothering, because as part of many brain 
donation schemes, in particular BDR, we have public meetings and we advertise 
these widely. They’re open to everybody, but you know who is going to come at 
the end of the day. 
59 The Guardian is a long-established British daily newspaper which has a reputation for being liberal and 
left wing. See comments by Professor Paul Francis on page 39 and note 60.
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Perry: That’s what I mean about the communication. People come because 
they feel that they’ll understand it and actually we don’t make enough effort to 
talk to the people at different levels. We all know there are different levels of 
understanding so if we don’t make that extra effort …
Francis: It’s really interesting what David says. I did an interview with Angela 
Clayton-Turner on Radio 4 on the Today programme just before 9 o’clock in 
the morning and I think we had 250 people contact us. And you know who 
listens to Radio 4 at five to nine in the morning: older, well-educated people.60 
But what’s interesting, we’ve had more difficulty recruiting in South Wales, 
where there is a small group in Cardiff who would be considered ‘middle class’ 
but outside that it’s a very working-class environment. Interestingly, the team 
there has been struggling to work out how to communicate with them but 
they’ve had a real success recently with targeting GP surgeries. I’m not quite sure 
how this will translate but they said they’ve had about 200 responses locally, so 
we’re hoping that this will perhaps get a wider socio-economic group. But these 
are people that look after their health, they’re concerned about their health, get 
all the treatments, etc. and they come into our study. So I have a question for 
Carol about CFAS: is that the same, do you have the same issues there? What’s 
your actuarial analysis of your cohort? 
Brayne: Because we attempt to recruit the whole population, we have the whole 
population there to ask about brain donation and generally it doesn’t influence 
the uptake that much. The thing is, we have built a relationship with the people 
in the study and we know who they are, before we go and ask them about 
brain donation. So the process is very different from the cold asking people to 
respond to a call or to come to a public meeting. Ours is so different because 
we’ve enumerated the population to begin with.
Perry: But the point is more that you have to communicate with everybody 
and if you communicate with people in Manchester then guess what? People in 
Manchester will turn up.
60 Angela Clayton-Turner is a retired physiotherapist who worked with dementia patients and cared for 
her husband with Alzheimer’s for 18 years. She carries out voluntary work for the Alzheimer’s Society 
and has been a research network volunteer since 2000. Professor Paul Francis wrote: ‘[This] slot on the 
Today programme resulted in a massive spike of callers in the following week and I know other centres 
received direct contact. Typically these people fall into a particular socio-economic group. We also had 
people contact us who were too young. The other point that may be being made is that death rates amongst 
our cohort were lower than expected, again probably because of the bias of self-referral to socio-economic 
class.’ Email to Ms Caroline Overy, 5 November 2014. 
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Brayne: But it’s Newcastle, Nottingham, and Gwynedd, and we’ve had brain 
donors across all of those, so it does cover the class spectrum but it doesn’t 
cover ethnicity at all and I think that is a very big issue. In CFAS we don’t have 
an ethnic minority arm. Despite many attempts to get funding for studies of 
dementia in ethnic minorities we were unsuccessful. 
Gveric: Just to continue on this theme. We never actually attempted to collect 
any data regarding ethnicity specifically for MS and Parkinson’s but I don’t 
remember anyone asking for it, so that’s probably the main reason we never 
did this. The other thing, talking about public perception of brain banking and 
all the problems we had, is that brain banking has never had any problems in 
my mind. I’ve been on the receiving end of public perception when one of our 
supporting charities decided to use celebrities and, although we’ve been trying 
over many years to approach absolutely everyone with MS and Parkinson’s in this 
country we had really limited success, it was kind of a steady stream of donors 
that kept the donor scheme going. But when the celebrities appeared it was 
a completely different story and it suddenly opened this whole area to people 
who never even considered brain banking, brain donation, or any kind of tissue 
donation.61 It wasn’t really a great thing to experience and we finally gave up on it.
61 See note 58.
Figure 13: Dr Djordje Gveric
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Perry: Could you elaborate on why it’s not been a good thing?
Gveric: It’s because the perception was of brain banking being an industry, that’s 
what came through. People were expecting us to collect their brains expediently, 
to speak to the brain collecting department, to someone in charge, and all sorts 
of things. Within a week we went from 40 to 4,000 enquiries and it was 2 of us 
dealing with all of this and battling with the perception of this brain bank being 
ready to receive all these people. It still remains a problem because we have far 
too many brains for our own capacity and that’s why I think this kind of steady 
approach where you employ people who are interested, rather than just those 
who can make it really popular, is a much better thing to do. 
Perry: Right, so celebrities are good in some instances. 
Jenkinson: We were talking about control tissue a moment ago and I thought I’d 
mention two specific collections. In 2005 Jeanne Bell set up the Sudden Death 
Brain Bank and then, of course, more recently, the MRC set up the control bank 
in Oxford specifically to collect control tissue to help address these problems.62 
62 Jeanne Bell is Emeritus Professor of Neuropathology at the University of Edinburgh, and founder of the 
MRC Sudden Death Brain and Tissue Bank, which was set up in Edinburgh in 2005 to collect post mortem 
tissue samples and organs of individuals who had died suddenly, with either normal brains or with a CNS 
or psychiatric disorder. See Appendix 2 and Millar et al. (2007). The UK MRC control brain bank is part 
of the Thomas Willis Brain Collection in Oxford and was set up in 2010 to address the shortage of normal 
brain tissue donation to be used as comparators in research.
Figure 14: Dr Joanna Jenkinson
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I think it’s quite interesting that both these aim to collect from younger people. 
It’s not the same demographic and this has been entirely possible. Actually that 
echoes what Carol said about having a diversity of approaches in the way that 
you’re dealing with brain banking. So prospective cohorts are important but our 
experience shows that they will capture a certain demographic. I think the Mind 
Over Matter project showed us very clearly how successful approaches to donation 
can be if you give people the right information and communicate clearly.63
Perry: I thought your comments chimed very well with what Djordje said. At 
the brain banking meeting the other week our lay member pointed out to us 
that if you take on lots of brains but then decide you’re not going to use them, 
this is a real betrayal of somebody giving tissue on the understanding that this is 
the last gift that they can give that might be useful.64 I think it is very difficult. 
I can understand how the Parkinson’s disease (PD) bank now finds itself in a 
difficult position with very large numbers of brains and so forth. I think you’re 
right that there are concerns that trying to turn it into an industry is not a smart 
thing, not that you were trying to.
Gveric: I think the main issue is not really betrayal of all those people who 
suddenly appeared, because they didn’t really expect much, they never thought of 
it. They saw Jane Asher holding a brain and they said: ‘That’s a great thing to do. 
Shall we just call them and leave our brains?’65 It’s more about those people who 
were registered for about 10–15 years on the donor scheme and they are becoming 
cases that are not really interesting to researchers. We know that someone with 
MS who is in their 70s is not exactly the best case to look at. We had loads 
of discussion about this and also with management boards and never came to 
anything meaningful – it was just ‘carry on’. But what can you do? You don’t 
want to disappoint people, it’s bad PR. I think it would be fair to go back and just 
explain that it’s not really what we want at this point, but it’s very difficult.
Shaw: In what way don’t you want the 70-year-old with MS?
Gveric: It’s just that people who were registered at some point and who have 
lived happily for about 20 years, occasionally ask: ‘I’m in my seventies now or 
eighties; am I really useful to you as a donor?’ 
63 See pages 14 and 28. 
64 Professor Hugh Perry wrote: ‘The lay member of the Brain Bank Management Group is Archbishop 
Douglas Lewins.’ Email to Ms Caroline Overy, 14 October 2014.
65 See note 58.
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Shaw: And do you feel able to say ‘no’?
Gveric: No, I don’t feel able to say ‘no’. You have to really judge the character 
over the phone and say: ‘How do you feel about it?’ and then it’s a discussion. 
We have quite a few of these cases.
Shaw: We have enquiries in the same way but we are able to say ‘no’ in a nice way. 
It’s explaining to people that actually it’s not going to be valuable for research.
Gveric: It’s more about the actual active approach, not just waiting for people 
to come into you, because we probably have more than 10,000 people on the 
donor scheme. Out of those 10,000 I’d say maybe 2,000 really shouldn’t be on 
the donor scheme for all sorts of reasons. 
Shaw: But you could, even at the time of death, say to the relatives, ‘Actually…’
Gveric: It’s very, very difficult. It’s very difficult because then it’s the lasting gift.
Shaw: I know, and you’re disappointing them. Yes, I understand.
Esiri: I think it can be difficult to predict what people are going to be interested 
in so, for example, we’ve actually got quite interested in looking at Alzheimer’s 
changes in people who have multiple sclerosis, and then we need people who are 
in their seventies and eighties and we find we haven’t got very many of them.66 
The other thing is that people increasingly want large numbers of cases. We 
used to be studying 10 cases and 10 controls and it’s gone up to 50 cases and 
50 controls. Now it’s going up to 500 cases and 500 controls, partly driven by 
the very large numbers of people that are needed to be studied in genetics. So I 
think it’s hard to predict exactly what could be valuable in future.
Francis: I completely sympathize with the approach and more recently I’ve 
actually started answering the telephone to people who ring up so I’ve now got 
practical experience of what people say when they’re on the phone. At BDR 
we’ve taken the approach that we want to keep a cohort of a particular size so 
actually now in some centres we’ve stopped recruiting and we’re telling people 
we’re only going to be able to take them on if people die from the cohort; we’re 
66 Professor Margaret Esiri wrote: ‘I was referring to ongoing research looking at the prevalence of Alzheimer-
type pathology in brains collected from people with MS dying at different ages. For completeness we needed 
to include cases that had died in their 70s and 80s – cases that, for the study of MS pathology itself, are not 
a high priority because most of the pathology is “burnt out” by that time and for people with MS to have 
lived that long implies that their pathology was only mild.’ Email to Ms Caroline Overy, 15 October 2014. 
For the abstract describing this work, see Ridgeon et al. (2014).
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going to maintain this cohort. We can say to people who ring up ad hoc and 
ask whether we’d like a brain, that for us the most valuable brains for research 
are those with clinical information, and that’s what BDR is about. Most people, 
when you talk to them and say that, understand and they feel that they’ve done 
something positive by offering the brain – it’s ‘Yes, well I’ve done that, that’s 
what my mother wanted’ or whatever, and they will then accept at that point 
that it’s not going to happen. 
The other thing that we do say to them, particularly when we might decline for 
other reasons, is that it would be unethical for us to keep brains in our collection 
that are never going to be used. I take Margaret’s point about what could be 
used and I know Seth has made a case, and Simon Lovestone67 has made a case, 
that we don’t need a huge number of Alzheimer brains because there are a lot 
already available in very end stage, but what you can do is keep those pieces 
that get requested more frequently. For example, with Alzheimer’s disease that 
would be the hippocampus – everybody wants hippocampus. They don’t all 
67 Simon Lovestone was Professor of Old Age Psychiatry at King’s College London until 2014 when he was 
appointed Professor of Translational Neuroscience at the University of Oxford. 
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need it, as David Mann routinely tells me in the Tissue Request Committee, 
not everybody needs to study the hippocampus. But there are ways of dealing 
with this and, in my limited experience, it is better if you’re honest with people; 
Gillian Hayes would say much more about this in her experience of dealing 
with people who ring up and say: ‘Can you take my mother’s brain?’ and so on.68 
Our commitment though, if they are part of our programme, is that we will do 
our best to recover the brain and put it into the brain bank, mostly so that we 
can get some sort of neuropathological diagnosis for the family, which is often 
quite an important thing. But if we also say that we will then dispose of the 
tissue if it is not being used or it’s not being requested, I think that’s something 
that we’ve got to move to: that we’re not going to keep these collections forever; 
people understand that they will have – I don’t want to use the phrase in the way 
that it’s used in a supermarket – a shelf life; these brains will be in the bank for 
a certain amount of time and then they will be replaced by other brains. I think 
that’s another concept that we perhaps ought to think about and Seth, I’m sure, 
is going to say more about that. 
Love: I was going to comment on something else. I don’t think it’s appropriate 
to have a ‘one size fits all’ approach to dealing with brains and I agree with 
you that if people have registered with brain banks and they’ve been on the 
donor register for several years it would be wrong not to accept their brains. 
But I don’t think that the sorts of brain you’ve been referring to need the same 
level of assessment as the brains that are going to be much more in demand by 
researchers. I think there are compromises to be made. What I was going to pick 
up on relates to the comments that Djordje made about people with multiple 
sclerosis who want to donate brains and died many, many years after the acute 
illness: some chronic neurological diseases are just much more difficult to study 
by looking at autopsy brains than others. A lot of the psychiatric diseases are 
like this. For example, schizophrenia is often a disease of adolescence and these 
people then survive into their sixties and seventies and you have to wonder 
how useful it is going to be to study their brains. That isn’t to say we shouldn’t 
do post mortem research in that sort of disease but I think we have to have a 
slightly more imaginative and different approach from the passive one of just 
saying: ‘If you’ve got the disease go on a donor register and when you eventually 
die we’ll examine your brain.’ We need to be latching on to other studies like 
68 Dr Gillian Hayes is Senior Manager at Brains for Dementia Research at King’s College London. She was 
invited to this Witness Seminar but was unable to attend.
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Biobank and various other ways to try to predict people who are at risk of 
diseases and who may die through other causes because otherwise I think we 
can expend a lot of money and not get an awful lot back.69 
Perry: The message I get from you, who are right at the front of the field, is that 
as long as the communication is transparent then it’s clear that you can build 
up a degree of trust and so forth. I think the sort of problem that Djordje gets 
is when there is someone at the end of the telephone who doesn’t know us, who 
says: ‘I want to give my brain’ and you have to think off-the-cuff: ‘What am I 
going to say?’ It’s pretty clear this is not going to be an easy conversation but 
transparency and honesty, given what we’ve heard about Alder Hey and other 
related issues, has got to be the way forward. Maybe one of the problems is 
that there are still many aspects of the process of research about which people 
have no idea what it actually involves. I think that research to most people is 
somebody standing around in a white coat holding something that looks like a 
dagger, which is actually a pipette, stirring some bottle – lots of senior figures 
like myself are asked to put on a white coat and sit by a microscope for some 
ridiculous reason for publicity purposes.70 This is called research and, of course, 
there are layers upon layers of different activities. I’m not sure in the context of 
brain banking, and actually many other areas of research, that we explain it well 
enough – what these many layers are. If we did, we might be in a position of 
some strength of being able to say: ‘Well, we could go so far but no further’; or 
‘Thank you, but it can’t contribute to this but it might contribute to that’; or 
‘We would have to assess it but you might be one of those people that we won’t 
need’. Until we start to educate the public at every level, and I take your point, 
David, I think it is a problem. I think there are clear socio-economic strata. 
There are people who watch these dreadful hospital programmes and it seems 
to me they end up with a bewildering degree of trust in how some doctor will 
diagnose the rarest disease known to man, or discover that 24 interventions will 
rescue the dying child and the child walks out… I think it’s so misleading and 
unless we’re honest and communicate with the public in a transparent way we 
69 The UK Biobank, established by the Wellcome Trust, the Medical Research Council, the Department 
of Health, the Scottish Government, and the Northwest Regional Development Agency, was launched 
in Manchester in 2006 to gather biological samples and medical and lifestyle data from 500,000 people 
aged 40 to 69. It is a long-term research programme to create a national database to improve prevention, 
diagnosis, and treatment of serious illness. See the website at www.ukbiobank.ac.uk/about-biobank-uk/ 
(visited 8 September 2014).
70 For a discussion on the image of the scientist see, for example, Flannery (2001).
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lead ourselves into exactly this problem: that a famous figure holds a brain and 
that is research; somehow, by diffusion, the great neuropathologist diagnoses 
what’s going on, just holding it in his hands. Clearly nonsense.
Gveric: I think our problem was slightly more complex than that because we 
were dealing with an intermediate level called charities and I was quite blessed 
to work for brain banks which were always supported by charities. Charities 
have a slightly different view of what we have, what is public perception of 
research and how we should go about explaining this and so forth. This was 
really the main issue – how do we tell these people honestly ‘This is not what 
we want’? Charities were not ready for that; they didn’t want us to do that. That 
was the main problem. The other problem, probably referring to recruiting 
younger people for brain banking, was the level of hope that you’re dealing 
with. When we tried to find these younger people with this particularly nasty 
form of MS who would be really good for brain banking we encountered a lot 
of hope among their parents because they were still hoping for this miraculous 
cure that would suddenly pull them out of this disease and that was it, and 
there was no question that we could talk about brain banking. Only when 
the hope disappeared could we then put this forward and tell them: ‘This is 
really something that we would like you to do if you are ready for it.’ 71 These 
people also seem to be very isolated, they don’t really belong to any branches 
of the charity or they’re not really visible, so that was another problem for us in 
developing all this strategy that we tried to put in place.
Perry: There are many layers. One of the things we don’t tell the public often 
enough is that actually most experiments fail and lots of research also fails. 
But because we don’t like to tell people this we paint ourselves into a corner of 
‘the hope is just around the corner and a pill will be a cure to everything from 
obesity to smoking’, which we all know is nonsense. 
What I’d like to do is now move us forward. I don’t like to use the phrase but I 
will – ‘post Alder Hey’. I’d like to know from the assembled company whether 
it had any good consequences. What were the good things that came out of this 
exposure of tissue pathology to a more public scrutiny? I have the feeling there 
are some good things that have come out of it and as a consequence of that it has 
71 Dr Djordje Gveric wrote: ‘This refers to our attempts to recruit people with rapidly progressive MS 
and is given in the context of trying to recruit younger people onto a donor scheme. Sadly this condition 
usually has a very short duration and patients rapidly deteriorate. Pathologically there is an abundance of 
inflammatory lesions in the CNS which are of particular interest to current MS research.’ Email to Ms 
Caroline Overy, 23 October 2014.
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changed procedures. Then I’m going to fast forward into how we think about 
modern banking – we’re now post ‘brain collections’, we’re now into serious 
brain banking – to make this a resource that really will make a difference to the 
lives of people living with difficult diseases. I think that would be a structure for 
the next little while. So, post Alder Hey – has it had good consequences?
Love: I think that standards of governance of brain banks have improved and 
to some extent that’s due to Alder Hey or due to all of the events that occurred 
after Alder Hey. I think also they’re much more uniform across the UK. There 
was an initial period when a lot of the general public were very suspicious of 
anything to do with tissue retention but I think that’s passed now. I think as a 
result of some of the procedures that were put in place there is a greater level of 
trust now in the process and in the operation of brain banks so I think those are 
all good things. 
Francis: It’s interesting what Seth says. The general public does not understand 
the Human Tissue Act; they don’t necessarily understand the Mental Capacity 
Act.72 Do they trust us that we’re operating it correctly? I don’t know. But it’s 
at least something you can point to. The governance structure is good to some 
extent. There are still things that need to be addressed, which are bureaucratic 
rather than helpful, for example as we’re having to document every slide that’s 
used because it is human tissue – every tissue slide that goes through the process. 
If it’s homogenate it’s still human tissue but it’s outside the Human Tissue Act. 
Now these things are a little bizarre in terms of their interpretation. If you can see 
cells it’s human tissue, if you can’t see cells it’s not human tissue according to the 
Act. There is a sort of bedding down of the way that these various governances 
will work and we are in a period where we haven’t reached perhaps optimal use. 
The other thing I would say, and this is a perennial problem, is the way that 
ethics committees deal with research tissue banks, as they call them. This can be 
very, very arbitrary. Now I know the Health Research Authority, under Jonathan 
Montgomery,73 is going to really tackle this and try and deal with it, but all of 
this has come out of the processes which have gone on. Eventually we’ll get to a 
good position but the good thing is that we can turn round to the general public 
72 The Human Tissue Act (2004) regulates the removal, storage, use, and disposal of human tissue. See www.
legislation.gov.uk/ukpga/2004/30 (visited 18 June 2014). The Mental Capacity Act (2005) is designed to 
protect those who lack the mental capacity to make decisions for themselves. See www.legislation.gov.uk/
ukpga/2005/9/introduction (visited 18 June 2014).
73 Jonathan Montgomery is Professor of Healthcare Law at UCL. He was appointed as the first Chair of the 
Health Research Authority in 2012 and is Chair of the Nuffield Council on Bioethics.
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and say that we are properly regulated. We might not like it as being optimal, I 
think in two or three years, maybe I’m being too optimistic, but I think it will 
be better and there will be a reasonable environment that promotes research, 
providing nothing happens with the European Union, which I understand has 
a new set of regulations that might interfere with our ability to look for clinical 
data and I’m not competent to comment on that. 
Esiri: I agree with most of what’s been said about the good things. From my 
own perspective the bad things outweigh the good things in that the red tape 
has got stronger and the consent forms have become so complicated that it’s just 
taking a sledge hammer to crack a nut for a lot of it. Shipman didn’t help with 
the changes that came in for death certification and so on that have made it 
even harder to get death to post mortem removal of the brain intervals down.74 
Perry: Tell us how Shipman influenced things.
Esiri: I think it’s because they’ve changed the rules about who can sign a death 
certificate. The other thing that’s had an effect is the change in GP behaviour, so 
that they’re often not there. The GP who saw the person alive last has to be the 
person to sign the death certificate, and there’s so much change in GP rotas that 
it can be quite hard to get hold of the person who last saw that person alive. The 
consequence is that we have death to PM intervals for brain removal that are far 
74 Harold Shipman, a GP in Hyde, Greater Manchester, murdered 215 patients between 1975 and 1998. 
The subsequent Shipman Inquiry highlighted deficiencies in death certification and proposed reforms to 
the Coroner Service, death certification and registration, and the pathology service; see the report online 
at www.gov.uk/government/uploads/system/uploads/attachment_data/file/273227/5854.pdf (visited 8 
September 2014).
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too long in this country. For example, in the Netherlands they have a brain bank 
in which the death to PM intervals are in the region of 6 hours, and ours are all 
too often 48 hours.75 So the value of the tissue is greatly reduced. I say greatly, 
there’s still a lot you can do with it, but certainly it would be more valuable if we 
could bring those times down, and there seems to be no understanding of the 
importance of this. GPs don’t give priority to signing a death certificate because 
they’ve got such a lot of living patients that they’ve got to look after. So they don’t 
give priority on a Monday morning to signing a death certificate. Things like this 
really get in the way of providing the best service. Do any of my colleagues agree?
Lantos: I think the immediate aftermath of Alder Hey was more positive to 
some extent, than negative. On the positive side we reviewed all the existing 
procedures. This we’d done anyway from time to time since our brain bank 
had been funded by the MRC and they requested regular audits. Yet we went 
through all the procedure to tidy up anything that may have been a problem. 
One problem that emerged was the future of the archival collection at the 
Maudsley and the Institute of Psychiatry; this later became the responsibility 
of King’s Clinical Neuroscience Centre (Department). This collection had been 
carefully catalogued. So that was what was on the positive side. On the negative 
side, and I have to agree with Margaret, the bureaucracy has become much 
heavier. Although the number of brains we received didn’t go down at all, all the 
procedures actually became more complicated.
Mann: It’s not only a question of getting the GPs to certify death in a reasonable 
period of time, but also there’s the interaction with the Coroner’s Service, which 
plays a part in the sense that Trusts, or our particular Trust and many other Trusts 
in the country, are not happy to allow even tissues consented for donation to be 
removed from the body until all elements of a potential Coroner’s Enquiry have 
been removed. They will only do that once they have physically seen the so-
called ‘green form’.76 This happened in our own Trust, not with a brain donation 
but another organ donation for research, where the tissues went for research, 
and then a Coroner’s Enquiry was subsequently called and the tissues were not 
there for assessment as part of that enquiry. As a result of that the Trust has put 
this blanket policy in place, that it’s not permissible even with the best of will by 
the mortuary staff. They’re quite happy to participate and reduce post mortem 
times, but they’re hide-bound by Trust bureaucracy. 
75 For the Netherlands Brain Bank see, for example, Ravid and Swaab (1993).
76 See note 43.
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Perry: It seems unlikely that it’s going to be the prospective donor who is going 
to push for a shorter PM time. It just seems to be one of those things. I find it 
hard to imagine people doing that – ‘I want my brain taken out within an hour 
of my death.’ 
Esiri: Relatives do try and do that sometimes; people do put pressure on a GP to 
get the death certificate signed, but they haven’t got a lot of power.
Perry: The question is where does the power reside to change this? We’re 
going to move into this new brain banking era where we don’t want to do just 
chemistry but we want to use all these other techniques that are now available. 
Where does the pressure reside?
Jenkinson: We’re aware that these issues existed with the green form and what 
we’ve done through the Network is work very closely with the Human Tissue 
Authority and the Chief Coroner to get to a position where we have an agreed 
set of guidance that will be available on their website for all of the banks, 
making it clear that the green form is not a legal requirement for donation to 
go ahead.77 The NHS Trusts have all been communicated with through their 
chief executives by Sally Davies informing them that the green form should not 
be required and that they should facilitate brain donation.78 So I think we are 
making as many steps forward as we can to clarify a lot of these issues with the 
donation process. 
Perry: Who is the ‘we’ exerting that pressure, Jo? 
Jenkinson: The UK Brain Banks Network.79 
Perry: People like Seth and Paul, is that what you’re doing? You’re leaning on 
somebody? 
Love: Yes. I think we can put pressure on the coroners and, although they 
don’t have to respond to that pressure, the Chief Coroner has responded very 
positively. I think it’s very much more difficult to put pressure on general 
practitioners in any sort of systematic way to respond quickly in terms of signing 
death certificates. I don’t know if families sometimes put pressure on individual 
general practitioners but I don’t think you can tackle that in a systematic way 
across the whole country. 
77 See comments by Dr Djordje Gveric on pages 60–61 and note 96.
78 Professor Dame Sally Davies (b. 1949) has been Chief Medical Officer for England since 2010.
79 See note 6.
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Brayne: I wonder whether it’s worth talking to the Royal College of GPs about 
it in terms of honouring their patients’ wishes and so on. I think it would need 
to come through some central primary care body and I guess the Royal College 
would be the obvious one.
Nally: There’s another issue which the UK Brain Bank Network is trying to 
address through James Ironside, its outgoing director80 – I think you know 
about this, Seth – and that is the NHSBT (National Health Service Blood and 
Transplant) Organ Donation scheme, which hasn’t included brain donation 
and has been reluctant to do so, is intending to formulate a policy about that 
and it hasn’t yet happened.
Love: I haven’t been directly involved in those discussions. As far as I am aware 
there is a possibility of including information about brain donation on their 
website but that’s probably as far as they’d be willing to go for the moment. Jo 
will correct me.
Nally: I think even that would be enormously helpful. I found, for instance, 
in my work in Northern Ireland that that’s come to a halt because there’s a 
presumption there that because the NHSBT’s official policy at the moment is 
not to support brain donation, that is not an area that they would want to enter 
in terms of supporting post mortem research into autism. 
Perry: So, if you are an organ donor for kidneys or corneas or whatever other 
tissues, you’re not necessarily a brain donor?
Nally: No, there’s no information given to you about the need for brain donation 
even in terms of links to the brain bank sites.
Jenkinson: I think as we continue to formulate our donation policies we need to 
be slightly careful because obviously brain banking has limited capacity to take 
these donations and we’ve already discussed today and many times the idea of 
raising expectations that we then can’t fulfil. Actually I’m not sure that we would 
drive towards including brain donation as part of the donor registration card. 
Yes, it would be good if there was increased information, which is why we’ve 
been discussing with NHSBT the idea of them including information about 
brain donation on their website. Similarly, when we’re talking to people about 
brain donation, perhaps predominantly those in the younger cohort, we might 
80 Professor James Ironside holds the Chair in Clinical Neuropathology at the University of Edinburgh, and 
was Director of the UK Brain Banks Network from 2009 to 2013.
The Development of Brain Banks in the UK c.1970–c.2010
53
talk to them more widely about organ donations; you’ve got more reciprocal 
discussions going on. I’m not sure that we would want to push the idea that you 
automatically consent to brain donation. 
Perry: Is this taking us away from the older idea that you took whatever came 
through the door to an increased requirement for selectivity because one can do 
a lot with the right material.
Love: We want to encourage the assessment of people who are going to donate 
their brains. We want to accrue a lot of clinical information and, if possible, 
biochemical and radiological information. We don’t want just to be contacted 
out of the blue after someone has died without having obtained that information, 
as the brain is then much less valuable for research. 
Can I just point to one thing which involves a different aspect of brain banking? 
This is a consequence of Alder Hey that has had a very deleterious impact 
on Brain UK, the virtual brain bank which is also supported by the Medical 
Research Council. James Nicoll and David Hilton are the directors of the Brain 
Bank.81 This is a registry of archival material relating to collections that weren’t 
obtained specifically for research, usually for diagnostic purposes and often 
coroners’ autopsies, but which cover a lot of things that aren’t included in the 
conventional brain banks. Before Alder Hey I had never heard of people wanting 
blocks or slides back after diagnostic assessment. I think the assumption was 
(and still is in Scotland) that they were part of the medical record, and they’ve 
been invaluable for quite a lot of research into entities that aren’t covered by the 
conventional brain banks. I think that if the next of kin want the tissue that 
hasn’t been used for diagnostic purposes to be reunited with the body for burial 
or cremation, it is entirely appropriate to return the tissue. What did change 
quite dramatically post Alder Hey, certainly in my experience in Bristol, was 
the expectation that not only would that unused tissue be returned, but also the 
blocks and glass slides would be returned for cremation and burial. We’ve had 
quite a lot of cases where, several years later, people including family members 
have been interested in that tissue and there’s been nothing left because, in the 
course of very brief discussions, usually with coroners’ officers, family members 
81 Brain Archive Information Network (BRAIN UK) is based at Southampton University. The project has 
catalogued over 60,000 tissue cases from holdings of neuropathology centres in the UK, which is made 
available for neurological research. Professor James Nicoll, the Director of Brain UK, has held the Chair of 
Neuropathology at Southampton since 2001. Dr David Hilton, Consultant Neuropathologist at Derriford 
Hospital, Plymouth, is Deputy Director of the project. See the website at www.southampton.ac.uk/brainuk/
index.page (visited 23 June 2014).
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have ticked the box saying we don’t want anything at all retained; everything 
should be returned for burial. I don’t know if Margaret and David have had this 
experience? 
Mann: I have had only one single case in my entire experience where relatives 
have actually requested slides, as well as the fixed residuum of a brain, for funeral 
arrangements. And in fact the funeral directors and crematoria hate that because 
cremating glass slides is an absolute nightmare, but tissue is relatively simple. 
Francis: That’s an interesting point. I don’t think we’ve had any BDR cases that 
have actually requested material back. Going back to the business about who 
should we target to help facilitate brain banks, I think Jo’s point is very strong, 
it’s something we’ve talked about already: don’t promise more than you can 
give; take the brains that you’ve got coming in; don’t open the door as wide as 
possible. What we can do is to try to address the point about raising the quality 
of tissue. The relationship between post mortem delay and quality of tissue is 
not exact – for some things it matters a lot, for other things it matters not a 
jot.82 But one of the things we can do is engage with GPs, and I’m pleased Seth 
made a note about the Royal College of GPs. I think the Alzheimer’s Society 
did have a focus group of GPs who they asked about how would they like 
to receive information about BDR and what would make a difference, and 
the results of that are available. Basically, it’s about information and on the 
basis of that, the Alzheimer’s Society target every GP surgery in the UK with 
information about BDR. That was probably a year ago now but the more that 
we can engage with GPs and persuade them that this is an important part of 
eventually helping patients – okay, it will be a generation further on – and the 
more we find out about research now, in the long term if we can improve and 
develop new treatments, it’s actually going to reduce the load. So it’s in the GP’s 
long-term interest – if they are junior GPs, rather than people who are about to 
retire – that we actually do this. The other people, and this is bureaucracy, are 
the R&D departments and the chief executives who control mortuaries. R&D 
departments in hospitals or Trusts gladly sign off projects, such as Brains for 
Dementia Research, and from the lack of communication with other people 
involved, mortuaries and chief executives, you’d think they weren’t on the 
same planet. So I think communication with these people is important, and 
particularly with the help of the MRC and anybody else we can muster, to really 
get a grip of these people and say: ‘You are holding up research. You are making 
the quality of tissue that is coming into brain banks less good than it might be.’ 
82 See, for example, Stan et al. (2006). 
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And it’s important – yet again in a review that I had that came yesterday: ‘Your 
post mortem delays are very long compared to Europe and the US.’ That’s a 
reason to reject a paper in any journal that goes to an American reviewer. Now 
Margaret says 48 hours;83 surely we can do better than that? Some of that’s about 
making small payments to morticians to ask: ‘Will you do this?’ Some of it, if 
the brain is coming from a bit further away, and BDR do this, is to say: ‘Right, 
let’s have same day courier rather than waiting till the next day.’ You can reduce 
post mortem delays to 8 hours, 12 hours or something like that. There are many 
practical things that we can do to facilitate that but we also need something 
going on at the highest possible level and, Seth, this is something that I’m sure 
you can facilitate in your new role.84 You are going to be all things to all men, I 
can see this. 
Love: Expectations… [Laughter] 
Francis: Catherine and Jo from the MRC have the ear of the highest level. It can 
happen, you know. Tanks can be driven across lawns to get this to happen. I’m 
not trying to be Bob Geldof in East Africa.85
83 See page 50. 
84 Professor Seth Love was appointed Director of the UK Brain Banks Network on 1 November 2013. 
85 Bob Geldof (b. 1951) is an Irish singer, songwriter, and political activist, who raised millions of pounds 
for famine relief in Africa, initially though his Band Aid single in 1984 and Live Aid concert in 1985.
Figure 17: Dr Djordje Gveric, Professor Seth Love, and Professor Peter Lantos
The Development of Brain Banks in the UK c.1970–c.2010
56
Moody: Seth’s in charge of the Network now and I’d like to see the brain banks 
really rally behind him and sort these problems out. During some of these 
discussions I was considering, goodness me, if all these issues are unresolved 
why don’t we in the MRC make things simpler? We could close some MRC-
supported banks down and just have one bank and make it work in one location, 
for example, through persuasion of the local coroners and the Trust. It’s slightly 
exasperating sitting here and hearing that the same issues are still going round 
and round – I would like to see a sea change in the next five years.
Perry: When were you involved, Catherine? 
Moody: I was involved in setting up the UK Brain Banks Network.86 Following 
a workshop organized by the MRC in October 2006, there was a UKCRC 
committee, chaired by Jonathan Montgomery with Jeanne Bell as deputy, that 
86 The UK Brain Banks Network includes the MRC supported brain tissue banks: Edinburgh Brain Banks; 
London Neurodegenerative Diseases Brain Bank; Newcastle Brain Tissue Resource; Sheffield Brain Tissue 
Bank; Thomas Willis Brain Collection, Oxford; Brain UK, Southampton. Also Charity/NHS partner 
banks: Cambridge Brain Bank; Manchester Brain Bank; Multiple Sclerosis Society and Parkinson’s UK 
Brain Bank; Queen Square Brain Bank for Neurological Disorders; South West Dementia Brain Bank; 
Brains for Dementia Research Co-ordinating Centre.
Figure 18: Dr Catherine Moody 
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looked at the potential of brain banking, because although research needs were 
opening up, there was a feeling that – amongst other things – tissue was available 
in the brain banks but it was underused.87 
A number of the funding major agencies, MRC included, got together to think 
in some depth about brain banking and what should be done in the UK. The 
UK Clinical Research Collaboration (UKCRC) committee looked at all the 
different angles of brain banking – and came up with the recommendation 
that there should be a co-ordinated UK Brain Banks Network and that, instead 
of banks operating just locally or for a particular disease or only for this set of 
patients or through a cohort, they should be connected in some way (see Figure 
19).88 The Brain Banks Network was set up by the MRC in 2009 under the 
Directorship of Professor James Ironside.89 Since then actually it’s gone from 
strength to strength and I’d also like to say one of its particular strengths is that 
a database was put on the web this year so prospective researchers can look in 
one place and see what tissue is held in each of the banks of the Network.90 The 
other thing I’d like to flag up is that in the last two or three years because there’s 
been a Network, because of the increased visibility of banks, some major genetic 
studies using human tissue have been possible in the dementias area, resulting 
in new gene discoveries made using brain material from the brain banks.91 So 
we really must build on this momentum and make sure that the banks are 
maximally used; we really must get together to sort these problems out to realise 
the full vision of the Network. 
87 Dr Catherine Moody and Dr Joanna Jenkinson added: ‘Other issues were recognized too – for example 
the Human Tissue Act had yet to bed down, NHS research funding was undergoing reorganization, the 
coroner issues that have been mentioned and issues of compatibility and interoperability to do with the 
different ways that tissue was collected and preserved and information/data was not documented and made 
accessible. It seemed that researchers were not sufficiently aware of what brain tissue was available and that 
it was of high quality, and therefore work was needed to make it easier for researchers to use this valuable 
tissue.’ Notes on draft transcript, 6 January 2014. 
88 Dr Catherine Moody added: ‘This was to provide operational efficiency to maximize the potential for 
high quality research across the full range of CNS disorders.’ Note on draft transcript, 6 January 2014.
89 For the aims of the Brain Banks Network, see note 6.
90 This database contains details of over 10,000 brains from all ten UK brain banks. See www.mrc.ac.uk/
research/facilities/brain-banks/tissue-database/ (visited 23 June 2014).
91 For example, tissue samples from brain banks in Manchester and Newcastle have been used in the study of 
Lewy Body dementia in Parkinson’s disease (Nalls et al. (2013)) and research into the presence of an altered 
gene in people with Alzheimer’s disease used tissue from the MRC London Neurodegenerative Diseases Brain 
Bank and the Manchester Brain Bank from Brains for Dementia Research (Guerreiro et al. (2013)). 
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Figure 19: Diagram of the proposed Brain Banks Network. Reproduced from UKCRC Brain 
Bank Strategy Advisory Committee (2008), with permission from the Medical Research Council. 
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Perry: Perhaps people recognize that dopamine and its relationship to 
Parkinson’s disease came out of post mortem material; acetylcholine and its 
role in Alzheimer’s disease came out of post mortem material. I suspect there’s 
nowhere in any of the public statements about the discovery of Trem2 in 
Alzheimer’s disease or recent genes in Parkinson’s disease that they actually came 
from post mortem material. 
Moody: I think that the brain banks are generally acknowledged in published 
papers; for example, the MRC London Neurodegenerative Diseases Brain Bank 
and the Manchester Brain Bank in the 2013 New England Journal of Medicine 
paper on the Trem2 variant in Alzheimer’s disease.92 
Perry: No, I’m sure it is in the paper but what we’re talking about is in no small 
part public perception: when you take some post mortem tissue it goes into 
something called research and just disappears into the background. Margaret 
already described herself as a back room girl so there is an element that if brain 
banking is going to be perceived as being successful and contributing as an 
important area of research then it needs to be clearly stated that the results came 
from tissue taken from people.
Moody: Yes, communication to the research community and the wider public 
about what comes out of the brain banking is really important.
Francis: Can I add to the genetics studies? There were two genetics studies 
which were talking about clustering: the first discovery was on a large sample 
with more than 16,000 people and a small percentage were neuropathologically 
diagnosed;93 there was a separate study with a modest sample size of 1,600 
people, all neuropathologically diagnosed, who confirmed the same finding.94 
So BDR actually contributed to that study in a small way. Something 
I always say about BDR is that actually we confirmed something that was 
done in a neuropathologically confirmed group to show that clustering was 
a major genetic correlated disease. So I think we can do more about that and 
I like your point. In terms of communicating and actually getting some of 
these problems solved, we run a series of ethics study days where we invite 
92 Guerreiro et al. (2013). Dr Catherine Moody added: ‘John Hardy uses the Sudden Death Brain Bank for 
his research.’ Email to Ms Caroline Overy, 30 October 2014. See, for example, Forabosco et al. (2013).
93 Harold et al. (2009). 
94 Corneveaux et al. (2010). 
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morticians, everybody.95 We’d love chief executives to come along so they hear 
about the project, so they understand about brain donation and what their role 
is: how you can make a difference to the process of brain donation. If you’re 
a neuropathologist you’re doing the diagnosis; if you’re a mortician you can 
make sure that the donation occurs and you’re fulfilling somebody’s wishes. 
Occasionally we’ve had people come along from Trust R&D departments. 
Those are the sort of things that we can do and if you do it in the mortuaries 
that are most closely linked with the brain banks then that’s one way of actually 
getting things to happen. That’s what we try to do.
Moody: Is there something from what you do in BDR that could be done more 
widely amongst the other banks in the Network then?
Francis: Seth would know because he’s been intimately involved. 
Love: This is with respect to what? Participation in GWAS (genome-wide 
association studies)? 
Francis: No, more generally – getting GPs or morticians to understand their 
importance in facilitating brain donation, making it happen more quickly is 
what I was thinking of. I don’t know if there was something else you wanted to 
pick up from that?
Moody: I’m afraid I don’t have any solutions for you but it does seem important 
to tackle this issue as a Network.
Love: This is being tackled. Quite a lot of the brain banks are involved in similar 
initiatives to address this. I know that locally we’ve been involved in initiatives 
with mortuaries and I know that the Parkinson’s Disease and MS Tissue Bank 
have been involved in some initiatives in working with mortuaries. James 
Ironside has pushed this and I will continue to push this on a pan-network 
basis. I think we’re all learning from each other and all doing similar things if 
we see that a particular approach works.
Gveric: If I can just add that the MRC fact sheet, which explained finally what’s 
legal and what’s not legal, has made a real difference to our daily lives and I can 
say freely that we don’t really experience problems with mortuaries any more.96 
95 For example, in May 2013, Brains for Dementia Research ran a one-day, multidisciplinary training event 
in Oxford, which covered the ethics of brain donation, the donor/carer perspective on donation, and the 
legal aspects of consent. Information supplied by Professor Paul Francis.
96 Guidance for hospital and mortuary staff for brain and spinal cord donations was issued by the Human 
Tissue Authority in 2013; see http://www.mrc.ac.uk/research/facilities/brain-banks/workshops-training-
reports/brain-donation-guidance-and-faqs/ (visited 11 February 2015).
The Development of Brain Banks in the UK c.1970–c.2010
61
GPs are still there and that has to be tackled on an individual level regardless of 
how you approach it, but the actual fact sheet really proved that the Network is 
working, that we can get this information across – I just need to fax this little 
bit of paper to the mortuaries and, regardless of the local NHS Trust rules, they 
will show much better understanding of what we’re doing. That’s really made a 
difference. So, yes, it’s clearly working and it will take time obviously and we all 
need to participate and really show that kind of enthusiasm as well and share it 
with the MRC Network. 
Perry: So, dealing with these structural issues about how to get better tissue, is 
critical. What I’m really keen to think about now is how to communicate to 
the public about why this is important. I think also that lurking around in the 
background of this conversation are the comments made about how people with 
some particular psychiatric diseases can see this as a threat. A good example, I just 
happened to think of, is that there are some people with deaf children, deaf people 
with deaf children who think that their deafness should be preserved. As we have 
heard, there are people with autism who feel that autism has something to offer. 
It suggests that we as a neuroscience community dealing with this interface with 
individuals and tissues are failing to convey a message that there is something 
Figure 20: Professor Hugh Perry
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really good that can be done. One of the parallels when you think about advances 
in any area of medicine is, of course, oncology. Oncology has made huge advances 
because of the access to post mortem tissue; this led to the stratification of 
disease and so forth. Are we failing the brain banking community, neuroscience 
community, failing to portray either the good things that we do and the successes, 
or what is it that we’re not doing that still leads to suspicion? Or is it something 
about the brain? Is it brain-ness and we’re not communicating in the right way? 
Gveric: Do we really need to work on public perception any more? I mean 
public memory – it has got a very small capacity. People are overwhelmed with a 
lot of things from recession to jobs to anything, so talking about brain banking 
and trying to kind of put it permanently in their memory is a lot of effort and 
really something we shouldn’t be doing. I just want to give you an example of 
the latest Alzheimer’s and Parkinson’s diseases conference in Florence.97 I went 
around looking at the posters and there were very, very few that used human 
tissue, or presented some kind of data on human tissue. My feeling is, using 
the analogy of a lunch, that research using human tissue is either starter or a 
dessert, very rarely a main course. So this is what we have to do: we have to 
work on researchers; we have to promote brain banking amongst researchers 
so they can use more tissue, produce better papers, better data, something that 
research journalists will pick up on. That’s how we’re going to end up in the 
public memory because there’s something coming out of it, something valuable 
that people might use as a future therapy and so on. So that’s the way around: 
work on researchers not the public. 
Mann: I would echo that, Djordje. I think there is a perception, possibly 
amongst young researchers, that the human post mortem brain is just too 
difficult to work with because we can’t control the course of the illness, and 
all the environmental and other factors that may determine the impact at said 
stage of the illness. We can’t control these in the way we can do with cells. We 
can do it with mice, we can do it with chickens, we can do it with worms, we 
can do it with flies, we can do it with virtually everything, but man. I think 
there’s a reluctance to actually do work with human tissues; the perception is 
that the problems of working with it outweigh the benefits. We can model 
things, do experiments that happen within weeks or months, and a PhD can be 
determined within a finite time as a result of that. 
97 The 11th International Congress on Alzheimer’s and Parkinson’s Disease was held in Florence in March 
2013 and was attended by more than 3,000 delegates. Selected proceedings of this meeting were published 
in the journal Neurodegenerative Diseases. Hanin et al. (2014). 
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Perry: But doesn’t this contrast with the Human Brain Project and the Human 
Connectome? Isn’t there a desire to have human at the front of it all?98
Mann: There is, yes, that’s right. Everything is labelled ‘human, human, human, 
human’ but do we use it? And we’ve talked a lot about how we can increase the 
availability of tissues, the collection of tissues, the better storage and quality of 
tissues, but are we actually using them more? I’m not actually sure that that is 
translating through to actual usage.99 
Love: The first thing is, I don’t think it’s necessarily a bad thing that human tissue 
is the starter and dessert but not the main course. I think to some extent that’s 
our role: we’re examining human tissue because it provides the basis of a lot of 
disease classification, it’s the starting point for the formulation of hypotheses as to 
what’s going wrong, and then those hypotheses get tested out in the worms or the 
mice or the rats or in whatever system you use to manipulate the environmental 
and experimental variables and to reduce the problems to questions that are quite 
simple. And when you think you’ve got the answer then for the dessert you come 
back and ask yourself does this actually apply to human brain tissue? So you 
validate your findings by looking at human brain tissue. I don’t think that that’s 
necessarily a bad thing. A recent example of MRC-funded work that generated 
a lot of publicity came from Giovanna Mallucci, who did a fantastic piece of 
research showing that accumulated protein in a particular neurodegenerative 
disease affects the endoplasmic reticulum stress response, and that’s probably one 
of the reasons why the cells don’t function normally.100 She couldn’t have done 
that research had people not looked first at human brains and seen that there was 
abnormal accumulation of these rather insoluble proteins which were affecting 
the function of the cell, and to produce an effective therapy she’ll need to go back 
98 The Human Brain Project is a European collaborative initiative, established in 2013, to use technologies 
in neuroscience, medicine, and computing to understand the human brain. See the website at www.
humanbrainproject.eu/en_GB (visited 29 September 2014). The Human Connectome is a collaborative 
project between the Laboratory of Neuro Imaging at UCLA and the Martinos Center for Biomedical 
Imaging, Massachusetts General Hospital ‘to construct a map of the complete structural and functional 
neural connections in vivo within and across individuals’; www.humanconnectomeproject.org (visited 29 
September 2014).
99 See comments by Dr Joanna Jenkinson on page 65. 
100 Professor Giovanna Mallucci is programme leader of the ‘Mechanisms of Neurotoxicity’ research 
programme at the MRC Toxicology Unit in Leicester. Her identification of a compound that prevents 
neurodegeneration in mice, and which could lead to the development of a drug to treat diseases such as 
Alzheimer’s and Parkinson’s, was widely reported in the media in October 2013. Moreno et al. (2013). 
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to human tissue to make sure that what she’s identified in the prion-affected mice 
actually applies in human brain tissue. That’s not a criticism; we don’t have to 
do everything from start to finish by studying human brain tissue. I simply don’t 
think we can do relevant mouse research unless we start off by looking at human 
brain tissue and then at the end of the day we just need to make sure that what 
we’ve observed in the mouse is real in terms of human disease. 
Lantos: I happen to disagree with David. I don’t think that the public is 
interested in fruit flies or in mice or in tissue culture; the public is interested 
in the human brain. Even the lay public shows great interest, since there is 
nothing more exciting as, for example, functional imaging, about which many 
reports have been published even in the popular press. Perhaps the reason for 
this interest is that this method is visually attractive, and ensured rapid progress 
in our understanding of how the normal and diseased brain works. I would 
not actually be so self-effacing as to say that the public is not interested in the 
human brain. The question of whether we are actually doing a good job in 
drawing the public attention to our work – that is a different issue. I personally 
think that actually the public finds these discoveries fascinating and not only 
‘Guardian readers’ but also a wider variety of people.101
Perry: I think one important thing from all of this, the functional imaging of 
course, is the man in the street actually thinks the brain is coloured. I’m sure it 
doesn’t matter. 
Love: The other thing is that it’s not all that surprising that so much of the 
research between the formulation of the hypotheses and the validation of the 
hypotheses is conducted in animals – more of that than there is examination 
of human brains. As you’ve said, most research hypotheses are proven wrong, 
most experiments don’t work, so it’s not surprising that an awful lot of things 
that are done to flies and zebra fish and mice turn out either not to work or to 
generate findings that aren’t really relevant. I think one thing that may lead on to 
something to talk about later is the point that Peter made about the study of the 
brain being so visual. I think to some extent that’s a limitation of the custodians 
of brain banks who have always been morphologists and neuropathologists. I 
don’t think that brain banking should just be visual. I don’t think we’ve done 
enough of the sort of biochemical and molecular genetic analysis that would 
maximize the value of the tissue that we have.
101 See page 38. 
The Development of Brain Banks in the UK c.1970–c.2010
65
Lantos: These investigations should form the bridge between functional 
neuroimaging, when one actually can see what is happening at a given psychological 
task inside the brain, and the tissues which we have in our brain banks. 
Brayne: That is incredibly difficult because by definition our brain donors 
do tend to live for some time after they have had a psychological experiment. 
Certainly you just have to set up huge cohorts with very regular testing and 
clearly UK Biobank is that kind of model, but you’re still going to get tiny 
numbers where you have that proximity of the measuring and the death.
Jenkinson: I’d like to dispute the idea that we’re not seeing increased use of 
the tissue. We’ve asked the MRC banks over a number of years to collect the 
information on how many samples they’re sending out and we are seeing an 
increase in the number of samples they’re sending out and the number of requests 
that they’re getting. The number of new users that are coming to brain banking 
through the database is a really exciting development; all banks in the Network, 
all ten banks in the UK, have been asked to collect this information about how 
many samples they’re sending out over 2013 and send that to the Network as 
part of their 2014 service support cost payments. So we are actually building up 
the evidence about how much this tissue is being used by researchers.102
Perry: So David, feeling welcome? 
Mann: I thought it was really important to document that we’re not just setting 
up a network that acquires, but we’re also setting up a network which utilizes, so 
that the rate of utilization at least matches or outweighs the rate of acquisition; 
that we’re just not stamp collecting, because that’s always the danger, isn’t it – 
that you feel you’re just collecting stamps at the end of the day?
Perry: David, since you were a pioneer of using enzyme biochemistry and 
biochemistry in frozen tissue, and given that the tissue collected is getting to be 
better quality, are we being ambitious enough about what we do with it? With 
all the problems of collecting these specimens, are the best analytical tools being 
brought to bear, are people really being ambitious enough or are they still just 
scratching the surface?
102 Performance criteria including the provision and use of samples is collected annually from the brain banks 
in the Network: ‘…Provision of samples – how many projects from the UK and overseas are supported by the 
brain banks in question and how many samples have been provided to each project? Have any new groups 
applied for tissue samples? What is the success rate for applications for tissue samples? Use of samples – how 
many papers are published as a result of the brain banking activity and how many patents are generated from 
this work?’ See www.mrc.ac.uk/research/facilities/brain-banks/measures-of-success (visited 27 October 2014). 
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Mann: I’m just a simple microscope man, I don’t understand genetics or worms 
and flies and things in test tubes. No, neuropathology has developed enormously 
over the years. We’ve moved away from an era where we poured coloured pink 
and blue solutions on things,103 and a bit of alchemy involving silver,104 and 
that was the be all and end all of neuropathology. [Laughter] But now with 
molecular pathology, we molecular neuropathologists deal with molecules, we 
don’t deal with stains any more. We can define a level of pathological change 
using these tools that far outweighs what is possible with the test tube. We have 
the tools to identify a single cell on a slide, and say what that cell is and what’s 
wrong with it.
Francis: There was a very lovely presentation at the Alzheimer’s Research UK 
conference early this year – Konrad Talbot talking about kinase activity and 
showing functional studies in post mortem human brain, which I’m really 
impressed with. He had all sorts of studies in the publication.105 Just in terms 
of people who use tissue, one of the things we’re quite keen to record, and I’m 
not sure whether the MRC is actually recording this, is whether the people who 
are requesting tissue are new to requesting tissue from brain banks? I think 
that’s quite a valuable thing to record. One of the things we do is try to help 
the people who come to us with a tissue request that doesn’t look particularly 
good, by feeding back information to help them to develop their tissue request 
and ask for the right things and the right numbers because it’s addressing the 
point that people think it’s very hard to work with human tissue. If we can show 
that we’re increasing the number and capacity of researchers who are prepared 
to work with human tissue we will get the new ideas because these are people 
coming from doing their studies on Drosophila, zebra fish, all these transgenic 
studies, and they’ll say: ‘Actually, why can’t I do that in human tissue as well?’ 
So I think that’s quite an important thing that we try and support, and perhaps 
we can at least record it.
Jenkinson: We’re not systematically recording whether each user is new but 
certainly with the database we’ve seen that a lot of the people registering for 
that database are young investigators; they’re not people we would normally 
103 An early histological technique in neuropathology was the H&E stain. The acidic dye eosin is used 
to stain basic (in the chemical sense) structures pink; the basic dye haematoxylin is used to stain acidic 
structures purple or blue. 
104 Silver stains are used to identify nerve cells and their processes.
105 Bomfim et al. (2012). 
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associate with brain banking who already know who to talk to about acquiring 
the tissue. So I think the database is reaching a new audience and actually the 
type of iteration you describe where the bank manager or administrator works 
with the person requesting the tissue to make sure that they’re getting the right 
samples from the right location from the right number of donors is actually 
the really important added value experience that the banks offer and we can’t 
underestimate the value of that. So actually having a system where people could 
just order tissue straightaway through the database isn’t what’s important, it’s 
making that connection and making sure that they’re getting the right samples 
that they need for their study.
Perry: I think it’s probably true to say that many people who work on flies do 
not understand what Brodmann areas are, or the cyto-architectonic subtleties of 
the thalamus, so this is probably very important. 
Esiri: I just wanted to make the point that the committees that decide how 
funding should be allocated also come into the equation here because if people 
who commit money for research are not themselves in favour of research on 
human tissues being performed, that’s going to get in the way of even keen 
researchers who want to do it. So there’s also a perception there that perhaps 
needs to change. 
Perry: Can I respond to that? I think it’s hugely important to recognize that 
all of these things are driven by peer review and that relates to my comment 
earlier about whether the PR that refers to the use of human post mortem 
tissue is good enough:106 if the research isn’t perceived as being a significant step 
forward then it’s always going to be seen as something in the background. As we 
captured in our comments right at the beginning of the meeting, it’s not clear 
sometimes whether human post mortem tissue studies are really setting the pace 
for the research. I think Djordje’s comment is quite important – are the animal 
models the drivers of how we think a disease is understood? People used to refer 
to Alzheimer’s transgenic mice in the title of their papers. Now they refer to 
‘Cure for Alzheimer’s disease’ in a paper and it turns out it’s research in mice or 
flies.107 I think that those working with human tissue not communicating the 
value of what they do is actually detrimental.
106 See page 59. 
107 See, for example, Franco and Cedazo-Minguez (2014). 
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Esiri: Well, the other thing that I was going to say in relation to communicating 
what you do is that we have tried, particularly Brenda has tried hard with the 
Brain Bank for Autism, to get articles and interviews into the public domain 
about what we’re trying to do because we’ve been so aware of the need to educate 
people. It’s terribly hard to get people to carry these articles and Brenda actually 
can talk to this more than I can, she has a lot of experience of trying.
Nally: Yes, I have and, as you say, very limited success but where we have been 
successful it has yielded a tremendous public response, a very positive public 
response. 
Perry: So this is trying to publish in national newspapers?
Nally: Yes, primarily.108 I think one of the basic issues that we haven’t mentioned 
and which does come into discussion with journalists and with members of the 
public, is the effect of attitudes to, and feelings about, death, which is inevitably 
associated with this whole area and sometimes negatively associated with it. So 
very often that’s an area that journalists want to look at.
Perry: They would like to explore the issues around death?
Nally: Explore public attitudes to it and how that might affect responsiveness 
to research appeals. I’m very aware that the research into autism faces very 
different issues and that emerged very clearly in this discussion today – issues 
about difficulties in reaching donors and the huge need for brain donation and 
the fact that research is being held back by a lack of tissue. I think that’s very 
different in autism research from all the other areas we’ve discussed. But, yes, 
I think there is a resistance in the media and I’m sure people are interested in 
this issue and aware of people’s resistance to issues connected with death. Also, 
professionally, people working in public services and also some charities who act 
as gatekeepers to the public and to the community that we are trying to reach, 
have their own personal resistances and their own sensitivities to the issues that 
concern people who are most directly affected by it – the issues I talked about 
earlier on about resistance to this research as being unnecessary and not in the 
area they would want it to be.109 
Perry: Karen, do you have anything you’d like to add to that? You’re a gatekeeper 
too between the patient and research.
108 An article on the UK Brain Bank for Autism was published in The Guardian two days before the annual 
World Autism Awareness Day held on 2 April. See Gentleman (2013).
109 See the discussion on pages 31–33. 
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Shaw: And researchers and medics. 
Perry: And death, you’re right there. We’ve hardly used the word ‘death’ at all. 
It’s probably quite important. When you have these discussions with people 
about donation, is death actually an important part of the conversation or is 
it that you simply avoid that bit and you talk about what’s going to happen 
afterwards?
Shaw: It can be either. When I said to you earlier about approaching people in 
an individual way, I think that’s quite important. So, yes, some people may want 
to talk about it in the context of them dying; other people absolutely don’t want 
to and would rather avoid that part of it and think about when they’re no longer 
going to be here and it’s going to be the relatives’ responsibility. So everybody’s 
quite different. One of the clinics that we do at Queen Square is the progressive 
supranuclear palsy (PSP) clinic. We have a palliative care consultant as part of 
a multidisciplinary team and I can work alongside her so we can explore issues 
of death and then about donating for research, but on other occasions we don’t 
have that and I don’t talk about death. It really depends on who the person is 
and which way they are wanting to take it.
Figure 21: Ms Karen Shaw
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Perry: If you were going to give some advice to Seth, for example, who is going 
to start a new PR campaign for brain banking - ‘only the right brains in the 
right bank’, ‘the very best bank for your brain’ – should the word ‘death’ appear? 
If we’re going to discuss post mortem tissue, should the word ‘death’ appear?
Shaw: You mean in the kind of promotion?
Perry: Yes. ‘When you die you can do something useful’ Maybe that’s not quite 
the way to put it but… ‘When you die’, ‘after your death’…
Shaw: Maybe, I think euphemisms are totally unhelpful. 
Perry: I’m interested, you say yes; not everybody else says yes. Then why don’t 
the press want to take your articles that deal with this? If everybody here thinks 
that’s fine, that’s just what people expect.
Lantos: Perhaps because we don’t have the right handle on it. The press endlessly 
deals with, and the BBC is obsessed with, assisted death. It’s spelled out quite 
clearly to the point that they describe in detail people travelling to a clinic in 
Switzerland where they are being, at their request, killed.110 So I don’t think that 
the public in general is averse to talking about death and I don’t think that it 
should be a problem. 
Can I come back to the wider problem of the future that you just mentioned, 
but which we haven’t discussed yet? I think the success of the brain banks, apart 
from the competence of those who run them, depends on two major factors: 
one is outside funding, and the other is public perception and support. This is 
where I seem to detect a slightly negative attitude on our behalf – we don’t think 
that our work on the brain is actually of interest to the public. If you were to ask 
the man on the Clapham omnibus, or in a few years’ time those on Crossrail,111 
which organ they would find most interesting, on account of its shape and 
function, I would say most people would choose the brain. Now that is only the 
normal brain. However, considering diseases of the nervous system, the public is 
interested in their prevention and cure; a few years ago it would have been a very 
different matter. Now we can say that some of the most frequent diseases involve, 
in one way or another, the brain. As a trustee of Alzheimer’s Research UK we 
110 Assisted suicide is illegal in the UK but is permitted in some circumstances in clinics in Switzerland (e.g. 
Dignitas). Between 2008 and 2012, 126 people from the UK travelled to Swiss clinics to die; see Gauthier 
et al. (2014). 
111 Crossrail is a new 73-mile railway line currently under construction to serve Greater London, tunnelling 
under central London. It is scheduled to open in 2018. 
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found that our funding, despite the recession, went up considerably because the 
public became aware of the devastating effect of Alzheimer’s disease. So I don’t 
think that there should be a problem, in principle, to make the public aware that 
actually brain tissue is being used. Every so often on a Thursday morning on the 
Today programme there is a report of a medical breakthrough, referring to The 
Lancet or New England Journal of Medicine and it quite often relates to a genetic 
discovery of one or another neurological disease. The public may not be aware 
that without the use of human tissue these discoveries would not have been 
possible. So I am actually more positive about future possibilities of spreading 
knowledge. I think we have to communicate and for this reason the Wellcome 
Trust, for instance, could make a series of documentary television films, if not 
already made, on the use of human tissue from the beginning of research to the 
present day: about the discoveries that would not have been possible without 
using human brain tissue. 
Gveric: I can say no to death in a new way because there is no real need to 
discuss death at any point. Death is obviously part of life, as it is, and for brain 
banking it’s basically that practical turning point when you can get the brain. 
So we have developed language already for dealing with death; we’re talking 
about a lasting gift and it’s just part of all this charitable culture of donating 
something, whether it’s money or whether it’s part of you, when the time comes. 
And that’s really about it. I’ve spoken to many, many people with MS and PD 
and have never mentioned death and they never asked about death apart from 
some practical issues about funerals and so on. So death is fine and most of the 
people are fine with it at a certain point in their life. So I guess we can just carry 
on as we have so far. 
Shaw: I think euphemisms such as ‘when the time comes’ are not particularly 
helpful.
Gveric: It works very well. And we are extremely happy with that.
Perry: Karen, you don’t use that kind of language?
Shaw: No. 
Perry: So what do you say?
Shaw: When you die. 
Perry: Why do you not like those euphemisms?
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Shaw: Because I’ve heard doctors using euphemisms: ‘when the time comes’ 
and actually I’ve seen patients getting the wrong end of the stick on that one; 
and ‘maybe we could have a piece of your brain when the time comes’ and the 
relative and the patient have thought that you mean some kind of therapeutic 
input in a bit of their brain. They didn’t realise it meant taking the brain when 
they died. So it can be misconstrued, I think.
Mann: Another common euphemism again is that we’re reluctant to talk about 
taking the brain as a whole; we hedge around and say: ‘We would like brain 
tissue’ as though it’s some kind of nebulous amount, and we can solve everything 
on a pin prick of tissue. We don’t like to say: ‘We’ll take the whole brain.’ I don’t 
understand why, but that’s the kind of medical euphemism that goes around, 
that pervades everything in life, anything to do with medicine; doctors speak 
in euphemisms. 
Brayne: Just to say that I agree with the sort of clear, clean language, to use the 
neurolinguistic programming term. When we were developing the donation 
programme we moved away from talking about ‘pieces of tissue’, we went to 
explicit description of how the brain is taken out because actually what it did 
was flush out all those misconceptions about what people think happens at 
post mortem. As regards talking about death and not beating about the bush, 
our experience in the older population – it may be different for different age 
Figure 22: Professor David Mann
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groups – was that it was on the whole welcome, and that people appreciated 
the opportunity to talk about their own death as they had not been able to raise 
it with their families. It was an opportunity for them to decide and to discuss 
whether they wanted to be cremated or buried and all of those sorts of things. 
That honest language triggered a whole load of other positive outcomes.
Francis: Yes, certainly in the BDR our experience is completely congruent with 
that. People will correct you if you’re not honest, and they will say: ‘yes, of 
course I’m going to die, I just want to sort it out.’ Even if you approach it 
cautiously, older people remain incautious. They will tell you exactly: ‘Well, I’m 
not going to need it, am I?’ It’s actually a surprisingly common response, so I 
don’t think there is an issue about mentioning death. As you say, Carol, it’s the 
practicality – they want to know whether they are going to be scarred? We tell 
them they can have an open casket if that’s what they want because removing 
the brain in a mortuary is not going to interfere. Even if you need to take the 
spinal cord it’s inevitably done from the back and you can still have an open 
casket. And people think: ‘Oh right, okay, that’s fine; I understand that process.’ 
It gets rid of these misconceptions – a ‘piece of tissue’, are we back to biopsies? 
It’s important that we’re honest with people. 
Perry: The discussion about ‘piece of tissue’ brings me back to something that 
David started with. Every day all over the UK there are dozens of neurosurgical 
units discarding bits of human brain tissue. You were saying earlier, David, how 
your early studies had benefited from taking tiny samples of fresh human tissues 
with which you can do all sorts of things that you might not otherwise do. It 
has always puzzled me that there isn’t a part of brain banking that involves the 
capture of small, half-centimetre cubes of post-surgical tissue, which I would 
have thought were invaluable. You could learn an enormous amount. Have you 
stopped doing this kind of thing, David?
Mann: Oh yes, a long time ago. I think the problem with taking cerebral biopsy 
is clearly the effect of the trauma in removing it. In that particular study we were 
taking something like 1–2cm cubes of tissue, but out of that 2cm cube of tissue 
probably 50 per cent was probably not usable because it was cauterized.112 There 
are practical problems, therefore, with using cerebral biopsy tissue. Interestingly, 
there have been a couple of papers out recently looking as to whether one can 
make, or to what extent one can make, an accurate diagnosis of dementia from 
simulated cerebral biopsies from post mortem tissue, taking small amounts out 
112 See, for example, Neary et al. (1986).
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to see how representative of the disease that might be.113 Whether that might be 
part of a groundswell of opinion that one should move back towards doing small 
cerebral biopsies for diagnosis, I don’t know. It seems to be quite an important 
issue that has surfaced in the literature.
Lantos: I think you raise a very important issue because by brain banking 
we automatically talked only of post mortem tissue and that is not the case. 
Some of the most interesting material we have are temporal lobe biopsies for 
epilepsy. That is important not only because it is from living patients and 
being a different type of tissue but also because, unlike dementia and other 
neurodegenerative brains that involve an advanced age group, we are here 
dealing with a much younger generation of people. In addition, we are also 
collecting tissues from brain tumours. Brain tumours in children, I think, are 
the second most common tumour type; so there is also emotional involvement 
on behalf of the parents. Going back again to what has become my hobbyhorse, 
actually brain banking should not be necessarily boring and something that the 
public doesn’t notice.
Francis: Picking up the point about biopsy and David’s comment about what 
you could get from somebody in their sixties as a biopsy and what might be 
safe and agreeable to any ethics committee which was investigating that, as 
I mentioned the control tissue we used to have was from people who were 
undergoing surgery for deep seated cranial tumours. Now my understanding 
is that the procedures have changed so much that they’re not removing normal 
tissue in order to gain access to these any more; they’re using much more 
sophisticated approaches. We also had tissue from the Brook General Hospital 
in London which was actually for subcaudate tractotomy so they were putting 
in radioactive yttrium rods into pathways underlying the frontal cortex, and 
then they would take out small pieces of tissue and we were investigating these. 
We were investigating depression, intractable depression.114 That’s not done here 
now but I think it is still done in one or two places in the USA so this tissue 
is potentially available. I think the amount of tissue is much less. Temporal 
lobectomies and so on, okay that’s a very specialized area, do form part of a 
wider brain bank, so to speak, but they will be much rarer than they were, say, 
20 years ago.
113 Venneti et al. (2011); King et al. (2013). 
114 See Bridges et al. (1994); Clarke et al. (1995); Clarke et al. (2011); Francis et al. (1989); Pangalos et al. 
(1992).
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Perry: So my attempt to get lots of fresh human tissue is obviously going to 
fail. There are a couple of other topics I’d like to touch on before we close. 
One of them is our relationship with industry. We have, over the years, had a 
fluctuating relationship with industry in neuroscience and people will know 
that in neurodegenerative disease it has waxed and waned, waned quite a lot 
recently and we hope that it’s now going to be revitalized. In multiple sclerosis, 
industry stepped back and then when things started to happen and looked 
hopeful from a therapeutic perspective, it came back again. How do we feel that 
industry should use our brain banks? Djordje, you’ve got an excess of brains; are 
industry clamouring to use your excess of brains?
Gveric: They are actually; we have a lot of people who are interested. However, 
we also have something called ‘Terms and Conditions’ which prevents us from 
giving it to absolutely every single company in the world, including the NIH in 
the United States. Obviously intellectual property (IP) is the hot issue between 
brain banks and the pharmaceutical industry. 
Perry: For all of us here: what is the issue?
Gveric: The issue is that there’s obviously a line referring to intellectual 
property in terms and conditions for every single tissue request, saying that 
they need to inform us of something that might be commercialized, something 
they might be making profit from, and so on. That’s the real problem: whether 
someone who is signing the contract in a pharmaceutical company will agree 
to it. There’s a lot of negotiation and renegotiation going on, obviously very 
complex if it starts involving the company, Imperial College lawyers, and 
charity lawyers as well. 
Perry: So the donor says: ‘I give my tissue; I don’t care who uses it as long as it’s 
for the benefit of humanity’, and then the bank says: ‘No, no, industry can’t use 
this because they might make a profit out of it.’
Gveric: No, we’re not saying that, we’re just saying that you have to sign terms 
and conditions so that if anything comes out of it we want you to share it with 
the people who funded it. That’s the only issue. 
Perry: Let me play devil’s advocate: is the donor aware that you’re going to do 
that?
Gveric: I’d say no.
Perry: Is that right? Is that ethically right?
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Gveric: It’s ethically right. That’s a big question, you know. We might go back 
to the example of HeLa cells and who benefits from that.115 I’ve quite often asked 
this question – whether a relative can expect anything out of the research that 
comes from using the tissue of their loved ones. I’m not sure. I don’t have the 
answer to this. I just know that we stick to these regulations that are hampering 
efforts to give tissue to pharmaceutical companies. But if we come up with an 
agreement, we quite often modify these things and they sign them. 
Perry: If you were going to give your bit of brain to a pharmaceutical company 
would you think it would be fine that it was used for the benefit of humanity?
Gveric: It’s absolutely fine.
Lantos: You should not forget that if there weren’t profit from pharmaceutical 
companies there wouldn’t be the Wellcome Trust.116 
Perry: I’m not against it, I’m just interested.
Jenkinson: I think that some of the terms and conditions that you’re describing 
around IP relate to particular charity conditions that are in place in your bank. 
In my experience, in a lot of the interactions that I’ve seen with industry, the 
problem is not so much the terms and conditions that the bank are asking 
industry to sign up to, it’s the terms and conditions that industry are then 
asking the banks to sign up to when supplying them that tissue. There have 
been cases recently where industry have wanted to get hold of tissue but then 
have specified within that that they owned that tissue and that goes against the 
spirit of the donation in the first place. 
Perry: The tissue or what they learn from the tissue?
Jenkinson: The tissue.
Perry: I see, okay.
115 HeLa cells form the oldest human immortal cell line most commonly used in scientific research. They 
were originally taken without permission from, and named after, cervical cancer patient Henrietta Lacks in 
1951. See Skloot (2010).
116 Sir Henry Wellcome (1853–1936) created the Wellcome Trust in his will dated 29 February 1932. It 
endowed two research charities, one to support the history of medicine and the other to support research in 
medical sciences. The Trust owned the umbrella organization, the Wellcome Foundation, which had been 
formed in 1924 by Sir Henry Wellcome to include his libraries, museums, research laboratories, and the 
pharmaceutical company of Burroughs Wellcome & Co. until it was partially floated on the stock market 
in 1986, eventually merging with Glaxo in 1995, and becoming part of GlaxoSmithKline in 2001. For a 
history of the pharmaceutical company, Burroughs Wellcome, see Church and Tansey (2007). 
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Brayne: The reason they want to own the tissue is that then they will be able to 
make profits on what they’ve discovered, is that right? 
Jenkinson: It’s the specification that they actually own the tissue that causes 
problems because it’s a donation. 
Brayne: This is a fascinating area, a really difficult one, and there are other areas 
where similar issues arise clearly in remote geographies, populations with very 
interesting genes etc. etc. Bronwyn Parry did go into this in some detail in her 
project, which was about the nature of ownership and the way that material is 
morphed into different things, and when you add IP, then who owns it? I think 
the collective custodian or steward – stewardship, was the model that came 
out from all of that work.117 The problem is that the pharmaceutical approach 
doesn’t fit that stewardship on behalf of humankind. 
Perry: Can I ask you just to pause there, so before you go to the next step. The 
stewardship model, which came out of the Nuffield Council on Bioethics report 
on Human Bodies: Donation for medicine and research,118 it begs the question: 
who benefits? As Peter just pointed out, if everybody benefits, because the 
company actually makes a new drug, what’s the problem? Somehow I just don’t 
117 Parry and Gere (2006).
118 Nuffield Council on Bioethics (2011). The report considered the ethical, social, and legal issues 
concerning the donation of bodily material for medicine and research.
Figure 23: Professor Carol Brayne and Dr Djordje Gveric
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understand how you can just turn around and say, ‘Yes, but it’s them. It’s them 
over there. We don’t want them to do something that they might make some 
money in order to help lots of other people. But we’d be very happy to do it in 
lots of other ways.’ I don’t quite understand. 
Brayne: It’s more that it remains under the bank’s stewardship, that’s the 
problem. It is incumbent the bank holds the ethical approval effectively so you 
can’t just sign it over to a pharmaceutical company. 
Perry: It depends on who and how they gave it, doesn’t it? If I give my brain for 
the good of humanity – full stop. If Djordje gets hold of it he won’t give it to 
industry. If I give it to Seth and he keeps it in a cupboard then he can give it to 
industry. I don’t understand this, why not?
Brayne: I suppose it’s the definition ‘for the good of humanity’. It’s a question 
of whether you are steward of the material for the common good; if you are 
steward of the material is it incumbent on you to know what happens with 
that tissue? I think the zeitgeist is that one should know what happens with the 
tissue and be able to track it. The finance I think is not so relevant. It’s the ‘what 
is being done’ with that tissue and is it for the good of humanity?
Reynolds: I suppose in 30 years I’ve been approached four or five times by industry 
wanting psychiatric post mortem cases and my approach has always been: ‘No, 
I’m not in a position to give them to you or sell them to you but you can support 
a project within the lab that we can monitor ourselves.’ On two or three occasions 
that has been the outcome, after some period of thought back at the company.
Perry: So is that an ethical fudge? 
Reynolds: Perhaps it is, although I think the question of stewardship, or the 
problems with stewardship are avoided, and it means that the research should 
progress.
Francis: Can I suggest another task for Seth? I would be happy to try and 
organize this through BDR but it would probably be better coming from the 
MRC; that is, perhaps if we have an ethics study day where we invite industry, 
ethicists, lay people, and make the point, ‘I’m giving my brain, why can’t it 
be used in industry?’, that sort of approach. I strongly feel, as you do, that if 
somebody is making that donation we should not stand in their way. But Carol 
makes a good point that the way that the Act is written at the moment is that 
we cannot transfer ownership and the HTA will be down on us like a ton of 
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bricks if we transfer it to somebody and we have no control over the disposal of 
that tissue. Now, I’m planning to use Gavin’s model in a project that I want to 
do with a pharmaceutical company. It can work but are we bending the rules to 
our own advantage by then attracting funding to university to do the project? 
And will the pharmaceutical company, or whoever they are, take all the data 
that you get? That in some way is fine because data is not the human tissue. So 
that could work or there could be some other way of getting around it. I think a 
group of ethicists – not too many otherwise we’ll have too many opinions – but 
actually an ethical debate where the pharmaceutical industry is present as well, 
and in the MRC Steering Committee we certainly have representatives from the 
pharmaceutical industry who can comment on this. 
Jenkinson: I don’t know if we need a group of experts to get together really, it’s 
already clear that this tissue absolutely can go to industry. There are examples 
of where this has worked. The difficulty comes down to individual terms and 
conditions and I’m not sure we’re going to get an industry standard template 
that they have to use – let’s just note that it is the terms and conditions the 
company sends to the bank that have caused the problem.
Love: Certainly in our limited experience of industrial requests the two critical 
things are: I don’t think we can ethically release tissue without being told what 
it’s going to be used for because all of us operate within some constraints. 
So, for example, the terms and conditions of our research ethics committee 
approval are, that this is research which is going to have, or has, the potential 
to be of benefit to people with dementia and/or their families. So we have to 
know something about what they are going to do to just make sure that we 
are conforming to the purposes for which we’re established, for which we have 
approval. The other thing which we need to be careful about is the principle 
of sharing of data. We’ve had quite a lot of discussion in previous meetings 
with the MRC that if you supply tissue to people and they generate data, they 
can use that data to commercialize a drug or whatever it is – that’s absolutely 
fine – but the raw data that enriches all of those donations should come back 
to the brain bank. And certainly that’s something people have been keen on 
in the past. I think the same standards should apply to industry. I don’t think 
that either of those things should prevent pharmaceutical companies from 
gaining information from the tissue and then using it to test ideas that they 
formulated in mice and then commercialize a product. I don’t think those 
are barriers. 
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Perry: I think that we should debate these issues. I’m not for one second saying 
that we should allow industry or anybody else carte blanche to do what they 
want to do. I think it is important in the nature of this kind of conversation 
that if somebody donates tissue, what are the limitations to what it is used 
for? I think it is a hugely important issue that the data that is collected from 
any type of analysis from a particular brain comes back to a database relating 
to that brain; this is the most useful way forward. Unfortunately I think right 
now what happens is that bits of tissue go to different places and the data are 
never assimilated in some way. If all this information came back to a source we 
would have a richness that would be truly valuable. I agree with you, we have 
to use these network data sources the right way. I don’t want anyone to imagine 
that I think industry, or anybody else, should do what they want to do. I want 
to know for the purposes of discussion: what are the rules and the limits that 
we have in place? I do think that the sorts of things that Paul and also Gavin 
have up their sleeves are good ways to do it. It takes advantage of the skills of 
industry, and the financial clout that industry may have, to make sure that tissue 
is used and then the information is released to the community. 
Mann: Going back to Djordje’s point, it may be an industrial misconception 
of the term ‘ownership’. Perhaps they think that we, as brain bankers, actually 
own the tissues we supply, whereas in fact we don’t. There’s no such thing as 
tissue ownership according to HTA. We are custodians of the tissue. We don’t 
own it. We may look after it and preserve it, distribute it and use it, though 
ultimately we don’t own it and there’s no way that industry can actually own 
any tissues either. As you say, if we’re working with industry, they have to have 
that appreciation that they cannot own the tissue, but they can work with us 
through a joint custodianship of the tissues but, ultimately, we need to know, 
as Seth has said, what has happened to that tissue, how it’s been used, how it’s 
been disposed of, has it been used ethically etc. etc. 
Reynolds: Back to the issue of data: I’m surprised you feel that most brain banks 
are not insisting that data is fed back.
Perry: No, they insist, the issue is whether it happens or not.
Reynolds: Certainly back in the 1980s it was instituted in Cambridge that 
those receiving tissue should feedback all the data and usually that was the 
case – usually more data than we could handle. I think the Stanley Medical 
Research Institute in the US do this extremely well; they have everything on 
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an open database, or open to all users, so there’s a lot of opportunity for data 
mining there.119 I would hope that the MRC would be doing this with their 
network anyway. 
Love: As rapidly as it can.120
Francis: Just one thing about ownership, David. If companies try us or anybody 
else and we’re too slow or there are terms and conditions, what happens is that 
they will go and buy the tissue – you can buy human tissue for research and 
essentially you have, or the company has, ownership of that tissue. So we’re 
119 The Stanley Neuropathology Consortium Integrative Database was established as a web-based tool to 
explore the neuropathology data from the Stanley Medical Research Institute to facilitate research into 
schizophrenia, bipolar disorder, and depression. See Kim and Webster (2010); and the website at http://
sncid.stanleyresearch.org (visited 24 September 2014).
120 Professor Seth Love wrote: ‘There isn’t a specific narrowly focused policy statement on the integration of 
research data but the MRC has included the statement “An ambition of the MRC Network over the next few 
years is to develop better systems for data storage and management, that will facilitate the integrated analysis of 
clinical, neuroradiological, molecular genetic, neuropathological and neurochemical data across the Network” 
in its description of the future plans for the MRC UK Brain Banks Network (www.mrc.ac.uk/research/facilities/
brain-banks/future-plans/ (visited 15 October 2015)).’ Email to Ms Caroline Overy, 15 October 2014. 
Figure 24: Professor Gavin Reynolds 
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competing against something that we know very little about but there are 
companies who will supply human tissue to other companies. I’m not sure 
what the ethics are; where they’re getting it; are these criminals in China or 
something? I’ve no idea. I really don’t know where they’re coming from. So 
there is this situation out there and that’s what companies are doing because 
they have a commercial agreement with another company to buy tissue.
Perry: Interactions with industry was obviously an exciting area to lead us 
towards the end of the day. The future of brain banking is more, bigger, better, 
bolder, under tight control, and information comes back to source. As Gavin 
says it does happen and I think it happens to some extent but not to the full 
extent that we hope it will. I think the results from brain banking are a huge and 
fantastic resource, and a fascinating resource. If there’s one thing that I’m left 
with a concern about, it is the PR. I think our outreach of what is learnt from 
the study of brain tissue could be integrated perhaps with what’s coming out of 
the imaging. There are fantastic imaging tools and somehow if we joined this 
up in the right way with brain banking, people could understand more about 
how post mortem tissue contributes to advance understanding not only of the 
diseased brain but understanding the healthy brain. Without it there would 
still be huge gaps in our knowledge. One also has to remember that there are 
structures of the human brain that don’t exist in other species. In non-human 
primates there are areas that match the human brain but once you study other 
vertebrates there are areas that do not. There are some special aspects of human 
brains and I think we also have to remember that many of the human diseases 
that people here and others study are peculiarly human. For example, there are 
claims to have generated autistic mice but I’m not sure that it’s quite so easy 
to judge whether this is indeed the case. Since we’re closing in on the end of 
the meeting, is there anyone who feels they would like to add anything, or say 
anything about human brain banking in the last 20 or 30 years, that has been 
missed? 
Mann: As a Yorkshire man I’m going to talk about value for money and brass 
– where’s t’brass for it all, lad? If we’re going to develop brain banking over 
the years to build up the resource and continue to use and improve it, it needs 
support. Support is tangible, let’s admit it. It is tangible and a resource that can 
be easily pulled away from us. What happens then?
Love: I feel like poacher turned gamekeeper here. I feel confident that support 
will be forthcoming if we show that we don’t just sit back and wait for it to 
come. We have to demonstrate continually that we’re doing things that are 
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useful, providing scientific value. If we continue to do that I’m sure we will 
continue to be supported. If we don’t do that we don’t deserve to be supported.
Lantos: This would require another four-hour discussion. 
Perry: Three minutes. 
Reynolds: Can I just say in some ways this session was very much meant to be 
a look backwards and we’ve talked a lot about the future. I’ve heard things from 
Seth and from others that I’ve actually heard over the past 20 to 30 years and 
there have been so many promises in the past that brain banking is the future. 
Back in the 1980s brain banking was the future and brain banking has shown 
itself to be effective and to be innovative and to give us new and important data 
but we’ve never really, really had a proper commitment from the Wellcome 
Trust, from the MRC that provides that strength that brain bankers have been 
looking for in their work.
Perry: Gavin, I’m not sure I want to go there at this late hour. 
Moody: Can I say for the record that the banks in the Network, the ones that 
MRC supports, have just secured a further five years of support from MRC. I 
appreciate there is charity funding and there are other types of bank but surely 
they are on a firmer footing now than they ever were in the past?
Reynolds: My point was really that this had been promised so much in the past 
and it is fantastic if it is happening now but there have been three decades of 
really underfunding that has restricted brain banking development.
Perry: Gavin, I think there’s actually a great message from Seth which is, why 
does imaging get lots of money? Because people like it and perceive that it has 
delivered important results. Whether you like what it delivers, there is a lot of 
debate around that too. It would be true of any area of science so I think the 
message about the PR associated with brain banking is that it’s hugely important. 
Finally, thank you all for coming and the last word is to Tilli. 
Tansey: I’d also like to thank you all very much for coming and for sharing your 
views and opinions, and thank Hugh in particular for being such an engaged 
and at times provocative chairman. Thank you.
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Appendix 1
Brain Banking Timeline121 
1950: Professor Nick Corsellis establishes the first brain collection in the UK at 
Runwell Hospital in Essex. 
1953: The MRC awards Professor Corsellis a research grant; the MRC’s support 
for research on the Corsellis collection continues for the next four decades. 
1957: Using donated brain tissue, Professor Arvid Carlsson demonstrates that 
dopamine is an important neurotransmitter and that low levels cause symptoms 
of Parkinson’s disease. His ground-breaking research leads to the development 
of l-dopa treatment. 
1964: The MRC publishes the UK’s first ethical principles to be observed by 
those undertaking medical research on patients.
1973: Professor Corsellis studies the brains of 15 former boxers and discovers 
the presence of amyloid plaques, a sign of dementia pugilistica, brain injury 
associated with boxing.
1974: MRC-supported scientists Dr Ted Bird and Professor Leslie Iversen show 
that a loss of gamma-aminobutyric acid-containing neurons in the basal ganglia 
is characteristic of Huntington’s chorea. 
1976–77: MRC-funded researchers, in parallel with two other research groups, 
discover the loss of choline acetyltransferase in cerebral cortical tissue from 
individuals affected by the plaque and tangle hallmarks of Alzheimer’s disease.
1984: Researchers George Glenner and Caine Wong identify ‘a novel 
cerebrovascular amyloid protein’ known as beta-amyloid – the chief component 
of Alzheimer’s brain plaques and a prime suspect in triggering nerve cell damage.
1986: CC75C starts a population-based brain donation programme linked to 
MRC Cambridge Brain Bank.122 
121  Timeline provided by Dr Joanna Jenkinson emphasizing MRC contributions.
122  Entry added by Professor Carol Brayne.
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1988: The MRC sets up Cognitive Function and Ageing Studies 1 (CFAS 1) to 
investigate dementia and cognitive decline in a representative sample of more 
than 18,000 people aged over 65 years. The study has been valuable in public 
policy decisions and in long-term projections.
1990: Wellcome Trust-funded research and brain collection identifies a deficit 
of a marker for GABAergic neuronal innervation to be reduced in schizophrenia, 
leading in 1997 to the identification of deficits in parvalbumin-containing 
neurons - the most robust neurochemcal finding in the disease.123
1991: MRC-funded research shows that decreased hippocampal expression of a 
glutamate receptor gene occurs in schizophrenia.
1991: A husband and wife team of researchers (Heiko & Eva Braak) undertake 
a detailed and painstaking examination of a large post mortem series of brains to 
establish a pattern of Alzheimer’s disease development as it spread from region 
to region. This staging of the disease is now used as a benchmark for disease 
severity, allowing changes that occur early in the disease to be studied and hence 
to be a focus of attention.
1996: Professor James Ironside identifies a new variant strain of Creutzfeldt-
Jakob disease using neuropathological examination, and suggests a link to BSE.
2005: The MRC Sudden Death Brain and Tissue Bank opens, providing 
researchers with access to the healthy brain tissue required for comparisons with 
tissue affected by central nervous system conditions in research.
2006: Research on donated brain tissue shows that TAR-DNA binding protein 
43 (TDP43) is the major disease protein in two neurodegenerative conditions 
–amyotrophic lateral sclerosis and frontotemporal dementia.
2007: MRC researcher characterizes gene Neuregulin 1, whose dysregulation 
has been linked to schizophrenia, and identifies a functional promoter variant 
associated with the condition.
2008: Using post mortem brains, scientists show that neurons in the fusiform 
gyrus area of the brain, involved with facial perception, are fewer and smaller 
in cases of autism.
123  Entry added by Professor Gavin Reynolds.
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2009: The MRC establishes the UK Brain Banks Network to coordinate the 
provision of brain tissue and to help tackle the shortage of samples available for 
research into neuroscience and mental health disorders. 
2013: The MRC launches a database of brain samples from more than 9,000 
donated human brains held across the Network of ten UK brain banks to enable 
researchers to search promptly for, identify, and request the tissue required for 
their work.

The Development of Brain Banks in the UK c.1970–c.2010 – Appendix 2
89
Appendix 2
The MRC Sudden Death and Tissue Bank124
The MRC Sudden Death and Tissue Bank was set up in Edinburgh in 2005 
in response to a need in the medical research community for access to ‘control’ 
tissue – that is the non-diseased tissue with which to compare diseased tissue 
when investigating abnormalities. 
Access to human tissue had become a contentious issue in the light of events 
leading to the Redfern and Isaacs reports and the subsequent loss of public 
confidence in the post mortem process.
The tissue bank started with a 24-month pilot to develop a mechanism by 
which relatives of individuals who had died suddenly and been autopsied under 
the Procurator Fiscal Service could be sensitively approached so that discussions 
surrounding tissue retention for research could be initiated. 
A key element in this has been the development of transparency; relatives are 
given a very strong voice in the retention process and are given the option to 
make tissues available to medical researchers.
Ninety-eight per cent of relatives approached supported research and gave 
authorization for tissues to be used for medical research purposes and positive 
feedback from relatives was received. The pilot study was followed by further 
funding from the MRC and, to date, the high success rate has been retained.
124  Text provided by Dr Joanna Jenkinson.
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Biographical notes*
* Contributors are asked to supply details; other entries are compiled from conventional 
biographical sources.
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MRCS LRCP FRCPsych FRCPath 
FRCP (1915–1994) qualified in 
medicine at the London Hospital in 
1944, and spent much of the next 
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recovering from tuberculosis. 
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neuroanatomy and pathology and 
following his recovery he joined 
the staff of Runwell Hospital, a 
long-stay mental hospital in Essex, 
where he went on to become 
Consultant Neuropathologist. 
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Chair of Neuropathology at the 
Institute of Psychiatry, a post that 
he held until his retirement.  It 
was at the Runwell Hospital that 
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125  Biography using material provided by Dr Joanna Jenkinson.
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development and translational 
biomarkers for dementia. He is 
Director of Brains for Dementia 
Research (BDR), a significant 
initiative in brain banking by the 
AS and ARUK and is a member of 
the MRC UK Brain Banks steering 
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Alzheimer’s disease and related 
disorders.
Dr Djordje Gveric
PhD (b. 1965) studied medicine 
at the University of Sarajevo 
(former Yugoslavia). He obtained 
a MSc in immunology at King’s 
College London and received a 
PhD in neuroimmunology from 
the University of London. From 
1994 until 2006 he worked at the 
Institute of Neurology where he 
was involved with the MS Society 
Tissue Bank and conducted 
research into pathogenesis of 
multiple sclerosis as a member of 
Professor Louise Cuzner’s group. In 
2008 he joined Imperial College as 
Manager of the MS and Parkinson’s 
Tissue Bank. 
Professor James Ironside 
CBE FRCPath, FRCPEdin, 
FMedSci, FRSE (b. 1954) 
graduated in Medicine from the 
University of Dundee in 1979. He 
was Senior Lecturer then Reader 
in Pathology at the University 
of Edinburgh and Honorary 
Consultant Neuropathologist at 
the Western General Hospitals 
Trust, Edinburgh from 1994 
to 2000. Since 2000, he has 
been Professor of Clinical 
Neuropathology at the University 
of Edinburgh and Honorary 
Consultant Neuropathologist and 
the Lothian University Hospital 
Division and Tayside University 
Hospitals Division. He is Director 
of Laboratories in the National 
CJD Research & Surveillance 
Unit, which identified the new 
variant form of CJD in 1996, 
and is currently a member of 
several advisory committees on 
CJD to the UK Government, 
the WHO, European Union and 
other international bodies. He was 
Director of the MRC Network 
of UK Brain Banks from 2009 to 
2013. 
Dr Joanna Jenkinson
PhD (b. 1977) received a PhD in 
fungal genetics from the University 
of Exeter, then undertook her 
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of the South West Dementia Brain 
Bank, President of the British 
Neuropathological Society, serves 
on multiple editorial boards and 
grant review committees, and 
was appointed Director of the 
UK Brain Banks Network in 
2013. He is the lead editor of 
Greenfield’s Neuropathology, and 
Editor-in-Chief-elect of Brain 
Pathology. His current research is 
supported by the Medical Research 
Council, Alzheimer’s Research UK, 
Alzheimer’s Society, British Heart 
Foundation, and BRACE, and 
is largely focused on Alzheimer’s 
disease and related causes of 
dementia.
Professor David Mann
PhD (b. 1948) studied zoology 
at the University of Durham, 
before completing his PhD 
in Neuropathology from the 
University of Manchester in 1972.  
His doctoral and postdoctoral 
work established a career interest 
in neurodegenerative diseases 
and brain banking. In 1976, 
he was appointed Lecturer in 
Neuropathology at the University 
of Manchester, and was promoted 
to Professor of Neuropathology in 
1998. He is Honorary Professor 
of Neuroscience at Salford Royal 
Hospitals NHS Foundation 
Trust, and Honorary Professor of 
Neuroscience at Beijing University 
of Chinese Medicine. He is a 
Fellow of the Royal College of 
Pathologists. He is coordinator 
of the Manchester Alzheimer’s 
Disease Research Centre within the 
Alzheimer’s Research UK Network, 
and Director of the Manchester 
BDR Brain Bank.  He has been a 
regular committee member of the 
British Neuropathological Society.
Dr Catherine Moody
PhD (b. 1957) received a PhD 
in pharmacology from the 
University of London, and her 
early postdoctoral career was in 
biomolecular research in London 
and the United States.  She joined 
the Medical Research Council in 
1991 and has since held a range 
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of different posts within MRC 
Head Office, with responsibility 
for scientific areas ranging from 
basic molecular work through 
to clinical studies.  From 2004 
until 2007 she gained experience 
of ethical, social, and legal issues 
while on secondment as Deputy 
Director to the Nuffield Council 
on Bioethics. MRC programme 
manager responsibilities within the 
Neurosciences and Mental Health 
Board group since 2007 have 
included imaging, brain banking, 
and dementias research.
Ms Brenda Nally
BA DSA (b. 1941) worked in a 
range of public sector services and 
Higher Education professional 
training courses over a 30-year 
period, which led to a strong focus 
on the promotion of better services 
for disabled people, particularly 
through partnership with them 
and their families. Between 1993 
and 2006, this focus turned to 
autism, working in the north of 
England and Northern Ireland for 
the National Autistic Society in 
project management and regional 
coordination. Since 2007, she has 
focused on the development of 
the UK Brain Bank for Autism & 
Related Developmental Research 
at Oxford, working as outreach 
coordinator of this programme. 
Her initial postgraduate 
qualification was in social work.
Professor Hugh Perry 
MA DPhil FMedSci (b. 1952) 
is Professor of Experimental 
Neuropathology at the University 
of Southampton (since 1998). 
He completed his DPhil at the 
University of Oxford (1977) and 
remained there as a Locke Fellow 
of the Royal Society (1982–1986) 
and Wellcome Trust Senior 
Research Fellow (1986 –1995). 
His research interests are in the 
field of neuroimmunology; his 
recent work focuses on interactions 
between the immune system 
and nervous system, and in 
particular how systemic infection 
and inflammation play a role 
in driving the progression of 
neurodegenerative disease. He has 
published more than 300 peer-
reviewed papers. He has sat on 
research advisory and funding 
panels for a number of different 
groups and chaired the Cellular 
and Molecular Neuroscience 
panel of the Wellcome Trust 
(2004–2007). He has acted as a 
consultant for biotechnology and 
pharmaceutical companies in the 
area of neuroinflammation and 
neurodegenerative disease. He was 
elected a Fellow of the Academy 
of Medical Sciences (2005), and 
was Deputy Chair of the Nuffield 
Council on Bioethics. He is Chair 
of the MRC Neuroscience and 
Mental Health Board (2012 –).  
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Professor Gavin Reynolds 
PhD (b. 1952) studied chemistry 
at the University of York and 
received a PhD in biochemistry 
from the University of London. 
His postdoctoral work in London 
and Vienna established his 
long-standing interests in the 
neurochemistry and pharmacology 
of schizophrenia and other 
neuropsychiatric disorders. He 
developed these research interests 
further while ‘brain-banking’ 
with the MRC in Cambridge 
and following an appointment 
in 1985 as Wellcome Lecturer at 
the University of Nottingham.  In 
1990 he moved to the University 
of Sheffield and in 2004 took 
up the Chair of Neuroscience at 
Queen’s University Belfast.  He 
is now Honorary Professor in the 
Biomedical Research Centre at 
Sheffield Hallam University and 
Professor Emeritus at Queen’s 
University Belfast. He was 
President of the British Association 
for Psychopharmacology (2008–
2010).   
Ms Karen Shaw
RMN (b. 1964) trained in 
psychiatric nursing and moved 
into neurology whilst practising 
as a dementia nurse specialist and 
coordinating a multidisciplinary 
memory clinic.  She joined 
the Queen Square Brain Bank 
for Neurological Disorders at 
UCL Institute of Neurology as 
research/brain donation nurse 
in December 2000, where she 
provides expert information and 
advice to healthcare professionals, 
and counselling and support to 
patients, relatives, and members 
of the public in relation to brain 
donation. Her role in the brain 
bank is to ensure that the rationale 
for donation is fully understood 
by patients and families during 
life, and that the pathological 
diagnosis and research findings 
are sensitively related to the 
family after the donation. On the 
occasions when a genetic mutation 
is indicated in a donated brain she 
provides genetic counselling to the 
relatives and ensures the results 
are appropriately received within 
a clinical neurogenetics service. 
She is interested in personal, 
cultural, and societal perceptions 
of the (donated) brain, and has 
carried out research exploring the 
experiences, beliefs, and attitudes 
of donor relatives to brain donation 
(Eatough, Shaw and Lees (2012)).
Professor Tilli Tansey
OBE PhD PhD DSc HonMRCP 
HonFRCP FMedSci (b. 1953) 
graduated in zoology from the 
University of Sheffield in 1974, 
and obtained her PhD in Octopus 
neurochemistry in 1978. She 
worked as a neuroscientist in the 
Stazione Zoologica Naples, the 
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Marine Laboratory in Plymouth, 
the MRC Brain Metabolism Unit, 
Edinburgh, and was a Multiple 
Sclerosis Society Research Fellow 
at St Thomas’ Hospital, London 
(1983–1986). After a short 
sabbatical break at the Wellcome 
Institute for the History of 
Medicine (WIHM), she took a 
second PhD in medical history 
on the career of Sir Henry Dale, 
and became a member of the 
academic staff of the WIHM, later 
the Wellcome Trust Centre for the 
History of Medicine at UCL. She 
became Professor of the History of 
Modern Medical Sciences at UCL 
in 2007 and moved to Queen Mary 
University of London (QMUL), 
with the same title, in 2010. With 
the late Sir Christopher Booth she 
created the History of Twentieth 
Century Medicine Group in the 
early 1990s, now the History of 
Modern Biomedicine Research 
Group at QMUL.
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